

CURRICULUM VITAE

STEVEN A. CURLEY, M.D. F.A.C.S.

Beginning July 1, 2018, through July 31, 2023, I became the Oncology Institute Director and Chief of Surgical Oncology at the Christus Trinity Mother Frances Hospital in Tyler, Texas where I collaborated with colleagues to develop multidisciplinary care programs for cancer patients and develop a center of excellence for clinical care and clinical research in northeast Texas. We built a fully integrated, state-of-the-art cancer treatment center to provide world class cancer care throughout the region. In September 2023 I formed my own independent cancer care and research consulting firm and I've been engaged by medical equipment and pharmaceutical companies; cancer centers in the U.S., the Philippines, and Africa; and researchers with novel cancer treatment devices to design clinical trials and assist with F.D.A. approval processes.

I was Professor and Chief of Surgical Oncology at the Baylor College of Medicine and a Professor in Nano- Materials Science at Rice University and at The University of Texas Medical School in Houston, Texas from January 1, 2014, through June 30, 2018. During that time, I was the Director of the local and regional CHI Oncology Service line at the Baylor St. Luke's Medical Center, and Associate Director for Clinical Affairs at the NCI-designated Dan L. Duncan Comprehensive Cancer Center at the Baylor College of Medicine. At the Baylor College of Medicine and at CHI Baylor St. Luke's Medical Center, we are committed to developing world class multidisciplinary care programs for patients with all types of cancer. The National Cancer Institute-designated Dan L. Duncan Cancer Center will lead basic, translational, and clinical research efforts to provide innovative, personalized cancer care for patients in Houston and surrounding areas. I was a Professor of Surgery at the University of Texas M. D. Anderson for 22 years prior to accepting the position at the Baylor College of Medicine. I was the Surgical Oncology Fellowship Program Director at M.D. Anderson for 19 years. My clinical duties involved providing surgical care for patients with hepatobiliary and gastrointestinal malignancies.

My research laboratory engaged in design, bench testing, preclinical testing, and then clinical testing of two devices which have successfully gone through the full FDA approval process. My laboratory studies have been truly translational and focus on the development of new treatments for patients with malignant and non-malignant diseases. The laboratory focused on testing a novel noninvasive radiofrequency electromagnetic field treatment device. We combined engineering, chemistry, physics, materials science, nanotechnology, and molecular biology to create teams with disparate backgrounds and training to work together to solve real world clinical problems. I am committed to developing novel approaches to diagnose and treat human disease to improve patient outcomes and reduce toxicities of standard therapies. I was also involved in the Baylor Global Health Initiatives program and have assisted with the development of surgical education and patient care programs in other countries.

GENERAL BIOGRAPHICAL INFORMATION

A. Personal

1. Full Name: Steven Alan Curley, MD
2. Citizenship: USA

B. Education

1. Undergraduate Education
1978 The University of New Mexico, Albuquerque, NM, BS, Biology
2. Medical Education or Graduate Education
1982 The University of Texas Medical School at Houston, MD, Medicine
3. Postgraduate
1982-1988 Clinical Residency, Surgery, The University of New Mexico Hospitals,
Albuquerque, NM, Raymond Doberneck, M.D., Ph.D., Residency Director
1988-1990 Surgical Oncology Fellowship, Surgical Oncology, The University of Texas
MD Anderson Cancer Center, Houston, TX, Charles M. Balch, M.D.

C. Academic Appointments

1. Faculty Position(s) at Baylor College of Medicine
2014-2018 Olga Keith Weiss Chair of Surgery, Baylor College of Medicine
2014-2018 Professor and Chief of Surgical Oncology, Baylor College of Medicine
2016-2018 Translational Biology & Molecular Medicine Graduate Program, Baylor
College of Medicine
2. Previous Faculty Position(s) at Other Institutions
1998-2013 Charles B. Barker Chair in Surgery, Division of Surgery, The University
of Texas MD Anderson Cancer Center
1998-2013 Professor, Department of Surgical Oncology, Division of Surgery, The
University of Texas M D Anderson Cancer Center
1993-1998 Associate Professor, Department of Surgical Oncology, Division of
Surgery, The University of Texas M.D. Anderson Cancer Center

1990-1993 Assistant Professor, Department of Surgical Oncology, Division of
Surgery, The University of Texas M. D. Anderson Cancer Center

1990-1992 Assistant Professor, Department of Surgery, University of Texas Medical
School, Houston

3. Faculty Appointments at Other Institutions

2006-2020 Adjunct Professor, Department of Mechanical Engineering and Materials
Science, Department of Nanoengineering, Rice University, Houston, TX

2011-2020 Professor, Graduate School of Biomedical Sciences, The University of
Texas Health Science Center at Houston

2012-2020 Adjunct Professor Mechanical Engineering and Materials Science,
Nanoengineering Rice University, Houston, TX

D. Other Advanced Training/Experience

1. Formal Sabbatical Leave - NA
2. Other Specialized Training Following Academic Appointment - NA

E. Other Information

1. Honors or Awards

- Department of Surgery Best Teacher Award voted by Surgical Residents Baylor College of Medicine 2018
- Marquis Who's Who Lifetime Achievement award 2018.
- Marquis Who's Who 2016-2022
- America's Top Doctors for Cancer, 2017-2022 Castle Connolly Medical LTD
- Texas Super Doctors 2016-2022, Texas Monthly
- Listed in America's Top Doctors for Castle Connolly, 2005-present.
- Houston Business Recognition Award Program Doctor, 2016
- Top Oncologist in Houston, International Association of Oncologists 2016
- Listed in America's Top Doctors for Cancer Database, 2014-present.
- Tribeca Disruptive Innovator Award, 2012
- Top 1% of Physicians by US News & World Report, 2012-2022
- Award for Excellence in Education, The University of Texas Academy of Health Science Educators, 2012
- Patients' Choice Award - America's Most Compassionate Doctors, 2001-2022

- Listed in Best Doctors in America Database - Honor, 2009-present.
- Patients' Choice Recognition, Consumer Research, 2008-2010
- Listed in Best Doctors in America Database, 2006-present.
- Excellence in Teaching, UT Center for Biomedical Engineering Summer Internship Program, 2005
- Ten papers chosen for Selected Readings in Surgery 1989-2005
- Medical Award of Excellence, Cancer Counseling, Inc., 2000
- Listed in Castle Connolly Edition of America's Top Doctors National Guide, 2000-present.
- University Cancer Foundation Fellowship, 1994
- Matrix Pharmaceutical Grant, 1993-1994
- PRS clinical Research Grant, 1992-1993
- Outstanding Teacher Award, Surgical Oncology Fellows, UT MD Anderson Cancer Center, 1992, 2001, 2011
- Dunn Foundation Grant, 1992-1993
- Smith, Kline & French Outstanding Research by a Fellow, UT MD Anderson Cancer Center, 1990
- American Cancer Society Clinical Fellowship Award, 1988-1989
- Department of Neuroscience Outstanding Student Award, 1982

2. **Board Eligibility/Certification** American Board of Surgery,
Initial Start date: 1/1989 End date: 7/1999

Recertification date: 10/1997 Expired: 7/2009

Recertification date: 10/2008 Expired: 7/2019

Recertification date: 12/2018 Expires: 12/2029

3. **Other Non-academic Positions**

1995-2013 Medical Director, Gastrointestinal Cancer Multidisciplinary Care Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX

1993-2013 Chief, Gastrointestinal Tumor Surgery, Department of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX

1991-1997	Medical Director, General Surgery Physicians' Assistants, The University of Texas M. D. Anderson Cancer Center, Houston, TX
1990-2009	Director, Surgical Oncology Fellowship Program, Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
1991-1996	Medical Director, Station 80, General Surgery Clinic, The University of Texas M. D. Anderson Cancer Center, Houston, TX
2014- 2018	Associate Director for Clinical Affairs, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX and Oncology Service Line Chief, CHI St. Luke's Medical Center, Houston, TX
2018- 2023	Northeast Texas Cancer and Research Institute Medical Director and Chief of Surgical Oncology, Christus Trinity Mother Frances Hospital, Tyler, TX
2023- present	Principal Consultant Cutting C Consulting, providing service to improve functionality and offer program design services to international cancer centers; design and implement pre-clinical and clinical trials for novel cancer treatment devices and drugs; and provide advice on medical equipment and drug optimization to medical companies

RESEARCH INFORMATION

A. Research Support (provide the following for each project)

- a. Non-invasive radiofrequency field induced thermal destruction of malignant cells in human hepatocellular cancer.

Physical Science-Oncology Centers (PSOC)

NIH/NCI U54 CA143837

Principal Investigator, Project 2

9/28/2009-7/31/2016

\$578,233 (\$254,839/year)

- b. Radiofrequency heating of nanoparticles for killing prostate cancer

Binational Science Foundation

BSF 2011435

Principal Investigator

9/1/2012-8/31/2016

\$180,000 (\$45,000/year)

c. Targeted Radiowave Therapy Fund

Kanzius Cancer Research Foundation

Development Fund

Principal Investigator

1/1/2003- 12/31/2016

\$1,550,000

d. Sponsored Research Agreement Studies to support FDA- approved clinical trials of noninvasive radiofrequency field therapy for pancreatic and hepatocellular cancer.

Neotherma Oncology

Principal Investigator

7/1/2015 – 6/30/2018

\$9,180,000.00

e. P30 Baylor College of Medicine Cancer

NIH/NCI

R023664-N7

Associate Director for Clinical Affairs

7/1/2015 – 6/30/2020

(2,020,895)

B. National Scientific Participation

1. Journal Editorial Boards, etc.

- Member, Editorial Board, The Cancer Bulletin, 1992-1997
- Member, Editorial Board, Annals of Surgical Oncology, 1994
- Member, Editorial Board, Bulletin of The National Cancer Institute of Italy, 1996
- Member, Editorial Board, European Journal of Surgical Science, 1996

- Member, Editorial Board, International Journal of Surgical Sciences, Cancer Reports, 1996
- Member, Editorial Board, International Journal of Surgical Investigation, 1998
- Associate Section Editor, Annals of Surgical Oncology, 2002
- Section Editor, Annals of Surgical Oncology, 2005
- Member, Journal of Interventional Oncology, B.C. Decker Inc. Publisher, 2007-present

Member, Editorial Board, International Journal of Green Nanotechnology: Biomedicine, Taylor & Francis Publishing Company, 2009

- Member, Editorial Board, International Journal of Green Nanotechnology: Materials Science & Engineering, Taylor & Francis Publishing Company, 2009
- Member, Editorial Board, International Journal of Green Nanotechnology: Physics & Chemistry, Taylor & Francis Publishing Company, 2009
- Member, International Journal of Surgical Oncology, 2009-present
- Gastrointestinal Disease Section Editor, Cancer, 2011-present
- Editor-in-Chief, Cancer Nanotechnology, 2014 – present
- Editorial Board, Journal Clinics in Oncology- Surgical Oncology, 2016 – present
- Editorial Board, Journal of Nanomedicine, 2017 - present

Editor-in-Chief, Cancer Nanotechnology 2014-present

Review Panels, etc.

- Grant Reviewer/Service on Study Sections:
- Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology, National Cancer Institute (NCI), Member, 2010-2017
- Combined Cancer Therapy with Thermal Ablation and Drug-Loaded Nano preparations, Israel Science Foundation, Member, 2011-2015
- Scientific Steering Committee, G. S. Hogan Gastrointestinal Research Fund, Member, 2011

Journal Reviewer:

- Reviewer, American Journal of Surgery

- Reviewer, Analytical Chemistry
- Reviewer, Annals of Surgery
- Reviewer, Archives of Surgery
- Reviewer, Cancer
- Reviewer, Current Pharmaceutical Design
- Reviewer, Digestive Diseases and Sciences
- Reviewer, Future Medicine
- Reviewer, Gene
- Reviewer, Hepatogastroenterology
- Reviewer, Hepatology
- Reviewer, HPB
- Reviewer, Journal National Cancer Institute
- Reviewer, Journal of Clinical Oncology
- Reviewer, Journal of Nanobiotechnology
- Reviewer, Journal of the American College of Surgeons
- Reviewer, Molecular Cancer Therapeutics
- Reviewer, Nanomedicine
- Reviewer, New England Journal of Medicine
- Reviewer, Process Biochemistry
- Reviewer, Surgery
- Reviewer, Theranostics
- Reviewer, Tumori
- Reviewer, IEEE
- Reviewer, Journal American Chemical Association
- Reviewer, Small
- Reviewer, Physics Reviews
- Member, Editorial Review Board, Hepatic Oncology, 2013-present
- Member, Editorial Board, Cancer 2011- present
- Editor-in-Chief, Cancer Nanotechnology, 2014 – present

2. **Professional Societies, etc.**

- American College of Surgeons, Member, Colorectal Cancer Collaborative Clinical Trials Group, 1996-2003
- American College of Surgeons, Member, Commission on Cancer Collaborative Clinical Trials Group, 1996-2010
- Society of University Surgeons, Member, Meeting Program Committee, 1996-1998
- American College of Surgeons, Commission on Cancer Fellowship Group, 2002-2018
- American College of Surgeons, Commission on Cancer Liver Disease Site Team, 2002-2005
- American Society of Clinical Oncology, Member, Program Committee, 2002-2004
- American Surgical Association, Member, 2002-present
- Society for Surgery of the Alimentary Tract, Member, Program Committee, 2004-2005
- Southwest Oncology Group, Member, Gastrointestinal Committee, 6/2006
- American College of Surgeons. Member, Education Committee, Commission on Cancer, 2/2007
- American Society of Clinical Oncology, Society of Surgical Oncology Representative, Steering Committee, Gastrointestinal Cancers Symposium, 2/2007-2011
- American Hepato-Pancreato-Biliary Association. Member, Committee on Emerging Technologies and Therapeutics, 2009
- Institute of Medicine, Member, National Cancer Policy Forum, 2009
- Society of Surgical Oncology. Member, Executive Council, 7/2009-2016
- American Association of Cancer Research
- American Hepato-Pancreato-Biliary Association
- American Medical Association
- American Society of Clinical Oncology
- Association of Academic Surgeons
- Italian Society of Surgical Oncology (Honorary)
- New Mexico Medical Society
- Society of Surgical Oncology
- Society of University Surgeons

- Southwestern Surgical Congress
- Surgical Biology III
- Harris County Medical Society
- Texas Medical Association
- SWOG, Member, 2014-2018

3. **Invited Lectures, Presentations, Research Seminars (national)**

- American College of Surgeons, Big Sky, MO, 8/1/1994
- American College of Surgeons, Chicago, IL, 10/1/1994
- American Association for the Study of Liver Diseases, Chicago, IL, 11/1/1994
- Radiological Society of North America Annual Meeting, Chicago, IL, 11/1/1994
- American College of Surgeons, New Orleans, LA, 10/1/1995
- Society for Surgery of the Alimentary Tract, San Francisco, CA, 5/1/1996
- New Mexico Annual Cancer Week, Albuquerque, NM, 9/1/1996
- California Oncology Symposium, La Jolla, CA, 10/1/1996
- Radiofrequency ablation (RFA) of malignant liver tumors, Sixth International Conference on Gastrointestinal Oncology, Williamsburg, VA, 10/1/1999
- Radiofrequency ablation versus cryoablation for liver tumors, American College of Surgeons, San Francisco, CA, 10/1/1999
- New technology for old disease (what's proven, what's not): Radiofrequency ablation of malignancy, American College of Surgeons, New Orleans, LA, 10/1/2001
- Update on treatment of primary and secondary hepatobiliary malignancy; long term outcome of ablative techniques, The Society of Surgical Oncology, Cancer Symposium, Denver, CO, 3/1/2002.
- Management of hepatic metastases: New ablation techniques, 3rd Annual Perspectives in Colorectal Cancer, Chicago, IL, 9/1/2002
- Surgical resection of non-colorectal hepatic metastases, Meet the Professor Session, Society of Surgical Oncology, Los Angeles, CA, 3/1/2003.
- Expert opinion: Interventions in the management of hepatic tumors, American Society of Clinical Oncology Annual Meeting, Chicago, IL, 5/1/2003
- Advances in hepatic and biliary cancer, Annual Clinical Science Symposium, Chicago, IL, 6/1/2003
- Radiofrequency ablation of liver metastases, 4th Annual Perspectives in Colorectal Cancer, Arlington, VA, 9/1/2003

- Surgical and radiologic approaches to ablative therapy for hepatoma, 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, 1/1/2004
- New clinical study protocols ongoing or in development, Society of Surgical Oncology Cancer Symposium, New York, NY, 3/1/2004
- Appropriate endpoints for liver-directed treatment of metastases, 2004 Gastrointestinal Oncology Conference International Society of Gastrointestinal Oncology, Arlington, VA, 7/1/2004
- Resection and radiofrequency ablation for metastatic liver disease for primary hepatocellular cancer, 6th Annual 2004 Cancer Congress, Savannah, GA, 11/1/2004
- Cancers of the colon and rectum: Local ablative approaches to liver-limited disease, 2005 Gastrointestinal Cancers Symposium, Hollywood, FL, 1/1/2005
- Breast cancer metastases: Local ablation and other methods of prolonging survival, 33rd Annual American College of Surgeons Spring Meeting, Hollywood, FL, 4/1/2005
- Ablation versus resection for malignant liver disease, 45th Annual Meeting of the Society for Surgery of the Alimentary Tract, Chicago, IL, 5/1/2005
- Complications, recurrence, and survival after radiofrequency ablation for hepatocellular carcinoma, Multidisciplinary Treatment of Pancreas, Liver and Biliary Tract Cancer Conference, Hyannis, MA, 6/1/2005
- Evolving therapies in colorectal cancer, American Society for Therapeutic Radiology and Oncology 47th Annual Meeting, Denver, CO, 10/1/2005
- Liver RFA: Surgeon's perspective, Society of Interventional Radiology Multimodality Symposia, Tyson's Corner, VA, 10/1/2005
- The impact of novel therapies on colorectal liver metastasis: Surgical, 6th Annual Oncology Update: Advances and Controversies, Park City, UT, 1/1/2006
- The treatment of primary hepatocellular carcinoma: Surgical, 6th Annual Oncology Update: Advances and Controversies, Park City, UT, 1/1/2006
- Surgical treatment of colorectal liver metastases: We must be aggressive, 2nd UT M. D. Anderson Cancer Center and M. D. Anderson Physician Annual Symposium, Kauai, HI, 6/1/2006.
- The evolving management of patients presenting with resectable stage IV colorectal cancer, 2nd UT M. D. Anderson Cancer Center and M. D. Anderson Physician Annual Symposium, Kauai, HI, 6/1/2006.
- Surgical advances in rectal cancer, Fifth International Colorectal Cancer Congress, Naples, FL, 10/1/2006
- Surgical treatment for patients with resectable hepatic and extrahepatic colorectal cancer metastases, Great Debates in GI Malignancies, Naples, FL, 12/2006

- The evolving management of patients presenting with stage IV colorectal cancer metastases, Great Debates in GI Malignancies, Naples, FL, 12/2006
- Case presentations: Pancreas/liver, 7th Annual Oncology Update: Advances and Controversies, Steamboat Springs, CO, 1/1/2007
- RFA for hepatocellular cancer, 5th International Hepatocellular Carcinoma. Eastern and Western Experiences Conference, Houston, TX, 1/1/2007
- Hepatocellular carcinoma: Clinical care and tumor biology; 2) Colorectal cancer/metastases: Biology, management and new chemotherapies; 3) The big debate, 32nd Annual Scientific Meeting of the Society of Interventional Radiology, Seattle, WA 3/2007
- Multi-modality management of primary and metastatic liver lesions, including bridge to transplant, 60th Annual Cancer Symposium, Society of Surgical Oncology, Washington, DC, 3/2007
- Pro: Open RFA of liver metastases ensures local control, 2007 SAGES Postgraduate Course and Scientific Session, Las Vegas, NV, 4/2007
- Changes in the playing field in surgical treatments for metastatic colorectal cancer; 2) Screening and treatment of hepatocellular cancer, 3rd UT M. D. Anderson Cancer Center and M. D Anderson Physicians Network Annual Symposium, Santa Barbara, TX, 7/2007
- 2nd Annual France-USA Science and Technology Workshop Nanotechnology and Cancer, Nanoparticles as intracellular targets to produce RF-induced thermal destruction of cancer cells, Houston, TX, 10/2007
- Multimodality care of the patient with synchronous CRC and liver metastasis, Sixth International Colorectal Cancer Congress, Fort Lauderdale, FL, 10/2007
- Should almost all patients with resectable or marginally resectable stage IV liver only metastatic disease receive neoadjuvant systemic therapy? Great Debates in GI Malignancies, Santa Monica, CA, 10/2007
- Nanoparticles as targets for RF-induced thermal destruction of cancer cells, Workshop of the NanoMedicine Study Group. Hyperthermia and Nanomaterials, Winston-Salem, NC, 4/7/2008
- Surgical approaches to resectable liver metastases, American Society of Clinical Oncology, Chicago, IL, 5/29/2008
- Liver ablation and nano-techniques, Translational Gastrointestinal Cancer Symposium, Seattle, WA, 10/25/2008
- Let's get small: Nanoparticles in the treatment of hepatic malignancies, American Society of Clinical Oncology, Orlando, FL, 6/2009
- From liver surgery to nanotechnology - What a long, strange trip it's been, Canadian Society of Surgical Oncology, Victoria, British Columbia, Canada, 9/2009

- Role of liver resection for gastro-esophageal malignancies, Canadian Society of Surgical Oncology, Victoria, British Columbia, Canada, 9/2009
- The role of thermal ablation and emerging technologies in the curative therapy of hepatocellular carcinoma, AHPBA Sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma, Orlando, FL, 1/2010
- Non-invasive radiofrequency treatment of cancer, Society of Surgical Oncology, St. Louis, MO, 3/2010
- Treatment of liver metastases - Surgery and ablative techniques for liver metastases, Society of Surgical Oncology, St. Louis, MO, 3/2010
- Interdisciplinary Cancer Treatment: The Importance of Timing, The University of Texas MD Anderson Cancer Center, New York, NY, 8/2010
- Radiofrequency ablation of unresectable liver lesions, Sixth Annual Symposium.
- Targeted gold nanoparticles and non-invasive RF treatment for cancer, Special Conference on Nano in Cancer: Linking Chemistry, Biology, and Clinical Applications in Vivo, American Association for Cancer Research, Miami, FL, 1/2011
- Noninvasive radiofrequency (RF) field heating of metallic and semiconducting nanoparticles, 219th Electrochemical Society, Montreal, Canada, 5/2011
- The future: Surgical treatment of liver malignancies, 9th Annual American College of Surgeons Clinical Congress, San Francisco, CA, 10/2011
- GI malignancies. Liver resection versus radiofrequency ablation for colon metastases and hepatocellular cancer, 10th Oncology Update: Advances and Controversies, The University of Texas M. D. Anderson Cancer Center, Steamboat Springs, CO, 1/2012
- Targeted therapy. Nanoparticle therapy: Fantasyland or reality? 10th Oncology Update: Advances and Controversies, The University of Texas M. D. Anderson Cancer Center, Steamboat Springs, CO, 1/2012
- Nanoparticles for thermal therapy in cancer, American Urological Association, Atlanta, GA, 5/2012
- Curative intent of colorectal cancer metastases, American Society of Clinical Oncology, Chicago, IL, 6/2012
- Nano-biomedical applications in cancer diagnosis and treatment, 98th Annual Clinical Congress of the American College of Surgeons, Chicago, IL, 10/2012
- Targeted Therapy: Nano-Particle Therapy: Is the Future Nearby? 11th Oncology Update: Advances and Controversies, University of Texas M. D. Anderson Cancer Center, Steamboat Springs, CO, 1/2013
- Meet the Professor Session: Complex Case Conference - Hepatobiliary, Society of Surgical Oncology, National Harbor, MD, 3/2013

- EMR-based hyperthermia to treat cancer, 30th Annual Denali Conference, Providence Health and Services Alaska, Wrangell, AK, 8/2013
- Surgical treatment of hepatic malignancies, Providence Health and Services Alaska, 30th Denali Oncology Conference, Wrangell, AK, 8/2013
- Radiofrequency ablation as first-line therapy of non-operable hepatocellular carcinoma: results from 1,168 patients, SSO 67th Cancer Symposium, Phoenix, AZ, 3/2014
- Non-invasive radiofrequency field-induced hyperthermia inhibits homologous recombination mediated repair of gemcitabine stalled replication forks, SSO 67th Cancer Symposium, Phoenix, AZ, 3/2014
- Central pancreatectomy and distal pancreatectomy for pancreatic neck lesions result in equivalent long-term pancreatic function and fistula formation, SSO 67th Cancer Symposium, Phoenix, AZ, 3/2014
- Nanotherapeutics-Will this be a magic bullet against cancer, MEDDOS MED Alumni Symposium and 20th Congress of MEDISS, Houston, TX, 5/2014
- 13th Oncology Update: Advances and Controversies, Steamboat Springs, CO 1/2015
- SSO International Career Development Program, Houston, TX, 3/2015
- Ohio State University Wexner Medical Center Surgery Grand Rounds, Columbus, OH, Maximally Invasive to Non-Invasive Therapies for Gastrointestinal Cancers: What a long, strange trip it's been! Columbus, OH, 4/2015
- 14th Oncology Update: *Advances and Controversies*, Nanotechnology and Cancer Applications, Steamboat Springs, CO, 1/2016
- SSO 2016 Annual Cancer Symposium, Liver Ablation: when why and how? Boston, MA, 3/2016
- MRS Spring Meeting 2016, Phoenix, AZ, 3/2016
- Chicago Surgical Society, Current and future treatments in HPB malignancies. Chicago, ILL, 4/2016
- BSLMC Research Symposium, from invasive to non-invasive treatments for liver cancers: what a long, strange trip it's been. Houston, TX 5/2016
- 21st Congress of the Michael E. DeBakey International Surgical Society, Current and future treatments for hepatic malignancies. Fajardo, Puerto Rico 6/2016
- 15th Oncology Update: Advances and Controversies, Nanotechnology in Cancer Care. Steamboat Springs, CO, 1/2017
- 16th Oncology Update: Advances and Controversies, 10 Year survival results from a prospective HCC screening program in 10,372 chronic hepatitis B or C virus-infected patients. Steamboat Springs, CO, 1/2018

4. **Invited Lectures, Presentations, Research Seminars (international)**

- Dietary factors in hepatocellular cancer, Second International Conference on Nutrition and Cancer, Naples, Italy, 10/1/1998
- New approaches to cholangiocarcinoma, Advanced Surgery Course, Italian Society of Surgery, Naples, Italy, 12/1/1998
- Radiofrequency ablation of unresectable hepatocellular carcinoma, Fourth Shanghai
- International Symposium on Liver Cancer and Hepatitis Liver Diseases in the New Millennium, Shanghai, China, 10/1/2000
- RF thermoablation of hepatic metastases: Indications, limitations, results, the M.D. Anderson Experience, Seventh Annual International Conference on Gastrointestinal Oncology, Arcachon, France, 10/1/2000
- Towards a new gold standard in the treatment of liver metastases from colorectal cancer, II International Course of Controversies in Surgery, Oviedo, Spain, 10/1/2000
- New trends in oncological surgery, XIV National Congress of the SPIGC Oncology Surgery Session, Ischia, Italy, 5/1/2001
- Oncological surgery and prevention, diagnosis and treatment of colorectal cancer, 20th Argentine Cancer Congress Oncological Surgery Session, Buenos Aires, Argentina, 6/1/2001
- How to design, implement and manage a surgical oncology data base; RFA and other ablation approaches for colorectal cancer, Australasian Gastrointestinal Trials Group Annual Scientific Meeting, Queensland, Australia, 8/1/2001
- New frontiers in surgical oncology for the elderly, XV Congress of SPIGC, Vibo Valentia, Italy, 6/1/2002.
- Emerging therapies, 3rd Annual Montreal Conference on Colorectal and Other GI Tract Cancers, Montreal, Canada, 9/1/2002
- Intraoperative ultrasound for hepatocellular cancer and state-of-the-art treatment for hepatocellular cancer, Epatocarcinoma - Dalla Epidemiologia alla Terapia, Naples, Italy, 11/1/2002
- Local treatment of breast cancer hepatic metastases, 2nd International Future of Breast Cancer Congress, Banff Springs, Canada, 8/1/2003
- Hepatocellular cancer: Resection, radiofrequency ablation, and ADI-PEG at the M.D. Anderson Cancer Center, Hong Kong-Shanghai International Liver Congress, Hong Kong, China, 2/1/2004
- Shifting paradigms in GI oncology: Liver and pancreas cancers, challenging cases, 15th International Congress on Anti-Cancer Treatment, Paris, France, 2/1/2004
- Hepatocellular carcinoma: Diagnosis and biopsy indications and Colorectal Cancer:

- Resection of liver metastases, II International Breast Cancer and I International
- Gastrointestinal Cancer Meeting, Bahia, Brazil, 4/1/2004
- Intraoperative ultrasound for hepatocellular cancer and state-of-the-art treatment for hepatocellular cancer, Epatocarcinoma - Dalla Epidemiologia alla Terapia, Naples, Italy, 4/1/2004
- Arginine depletion therapy, 4th International Meeting on Hepatocellular Cancer: Eastern and Western Experiences, Hong Kong, China, 12/1/2004
- Radiofrequency ablation: A surgeon's perspective, 4th International Meeting on Hepatocellular Cancer: Eastern and Western Experiences, Hong Kong, China, 12/1/2004
- Hepatic colorectal metastases: Resection and ablation, Society of Interventional Radiology Foundation, Cooperative Alliance for Interventional Research, Toronto, Canada, 3/1/2006
- Management of the patient with liver metastasis from colorectal cancer, American College of Surgeons Puerto Rico Chapter, San Juan, PR, 2/2008
- From liver surgery to nanotechnology - What a long, strange trip it's been, Canadian Society of Surgical Oncology, Victoria, British Columbia, Canada, 9/2009
- Role of liver resection for gastro-esophageal malignancies, Canadian Society of Surgical Oncology, Victoria, British Columbia, Canada, 9/2009
- Advances in hepatic surgery: Ultrasound principles, 9th World Congress of the IHPBA, Buenos Aires, Argentina, 4/2010
- Nonfunctioning endocrine pancreatic tumors: Ablation therapies, 9th World Congress of the IHPBA, Buenos Aires, Argentina, 4/2010
- Use of targeted nanoparticles for non-invasive RF thermal destruction of cancer cells, International Meeting Nano-Biomedicine, Mercogliano, Italy, 6/2010
- Issues in delivery of targeted nanoparticles to cancer cells for non-invasive radiofrequency thermal ablation, Nano-Gagliato 2010, Gagliato, Italy, 7/2010
- European Society Surgical Oncology, Italy, 9/2015
- BSLMC Embassy, Oncology Service Line, Current and Future Management of Liver Malignancies. Guadalajara, Mexico, 11/2015
- C3 Saudi International Healthcare Forum, Riyadh, Saudi Arabia, 4/2016
- 15th Middle East Surgery Conference, Arab Health Congress, Electromagnetic fields combined with targeted nanoparticles to produce hyperthermic killing of cancer cells. Surgical treatment of liver tumors. Dubai, 1/2016
- 15th Middle East Surgery Conference, Arab Health Congress, Surgical treatment liver tumors. Historical, current, and future trends in surgical and multidisciplinary treatment of colorectal cancer liver metastases. Dubai, 1/2016

- BSLMC Embassy, Oncology Service Line, Congreso Oncologia al Limite III. Guadalajara, Mexico, 12/2016
- The Italian National Ministry of Health Protocol Development Meeting, Novel bioengineering approaches to treat malignant disease. Rome, Italy, 2/2017
- BSLMC International Honduras Medical Conference, Non-invasive electromagnetic therapy for cancer. Tegucigalpa, Honduras, 2/2017
- BSLMC International, Annual International Congress, Mexican Oncology Society. How to increase resectability of liver metastasis: which option to choose, portal embolization, hepatectomy in 2 stages, liver transplantation, radiofrequency. Queretaro, Mexico, 10/2017.

C. Publications: Full Papers in Peer Reviewed Journals

1. **Curley SA**, Allison DC. Alterations in cell cycle kinetics with changes in tumor size. *Surg Forum* 37:407-409, 1986.
2. **Curley SA**, Weaver W, Wilkinson LH, Demarest GB. Late complications after gastric reservoir reduction with external wrap. *Arch Surg* 122:781-783, 1987.
3. **Curley SA**, Allison DC, Smith DE, Doberneck RC. Analysis of techniques and results in 347 consecutive colon anastomoses. *Am J Surg* 155:597-601, 1988.
4. **Curley SA**, Osler T, Demaraest GB. Vascular and brachial plexus injury in a patient with Ehlers-Danlos syndrome. *J Emer Med* 17:850-852, 1988.
5. Allison DC, Bose KK, Anderson S, **Curley SA**, Robertson J. Slowing of cell cycle traverse for cells in exponential momolayer cultures placed into plateau-fed and starved medium. *Cancer Res* 49:1456-1464, 1989.
6. **Curley SA**, Roh MS, Rich TA. Surgical therapy of early rectal carcinoma. *Hematol Oncol Clin North Am* 3:87-102, 1989.
7. **Curley SA**, Ablin DS, Kosloske AM. Giant cystic hygroma of the posterior mediastinum. *J Pediatr Surg* 24:398-400, 1989.
8. Bose KK, **Curley SA**, Smith WJ, Allison DC. Differences in the flow and absorption cytometric DNA distributions of mouse hepatocytes and tumor cells. *Cytometry* 10:388-393, 7/1989.
9. **Curley SA**, Klostergaard J, Roh MS. Kupffer cell production of tumor necrosis factor mediates killing of a murine colon adenocarcinoma. *Surg Forum* 40:396-398, 1989.
10. Roh MS, Wang L, Oyedeji C, LeRoux ME, **Curley SA**, Pollock RE, Klostergaard J. Human Kupffer cells are cytotoxic against human colon adenocarcinoma. *Surgery* 108:400-404; discussion 404-5, 8/1990.
11. **Curley SA**, Roh MS. Advances in the detection and treatment of colorectal carcinoma. *Compr Ther* 16:19-24, 1990.

12. **Curley SA**, Hohn DC, Roh MS. Hepatic artery infusion pumps: cannulation techniques and other surgical considerations. *Langenbecks Arch Chir* 375:119-Q24, 1990.
13. **Curley SA**, Klostergaard J, Roh MS. Human Kupffer cells produce cytotoxic monokines. *Surg Forum* 41:438-440, 1990.
14. **Curley SA**, Roh MS, Kleinerman E, Klostergaard J. Human recombinant macrophage colony stimulating factor activates murine Kupffer cells to a cytotoxic state. *Lymphokine Res* 9:355-363, 1990.
15. **Curley SA**, Byrd DR, Newman RA, Carrasco CH, Cromeens D, Ellis HJ, Chase J, Dougherty T, Wright K, Bodden W, Hohn DC. Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration: a feasibility study of a novel system. *Anticancer Drugs* 2:175-183, 4/1991.
16. Talamonti MS, Roh MS, **Curley SA**, Gallick GE. The c-SRC oncogene participates in the development of human colorectal liver metastases. *Surg Forum* 42:422-424, 1991.
17. Shumate CR, **Curley SA**, Cleary KR, Ames FC. Traumatic neuroma of the bile duct causing cholangitis and atrophy of the right hepatic lobe. *South Med J* 85:425-427, 4/1992.
18. **Curley SA**, Carlson GW, Shumate CR, Wishnow KI, Ames FC. Extended resection for locally advanced colorectal carcinoma. *Am J Surg* 163:553-559, 6/1992.
19. Fuhrman GM, Talamonti MS, **Curley SA**. Sphincter-preserving extended resection for locally advanced rectosigmoid carcinoma involving the urinary bladder. *J Surg Oncol* 50:77-80, 6/1992.
20. Roh MS, Kahky MP, Oyediji C, Klostergaard J, Wang L, **Curley SA**, Lotzova E. Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases. *Clin Exp Metastasis* 10:317-327, 9/1992.
21. Demers ML, **Curley SA**, Romsdahl MM. Inferior vena cava leiomyosarcoma. *J Surg Oncol* 51:89-92; discussion 92-3, 10/1992.
22. Granfield CA, Charnsangavej C, Dubrow RA, Varma DG, **Curley SA**, Whitley NO, Wallace S. Regional lymph node metastases in carcinoma of the left side of the colon and rectum: CT demonstration. *AJR Am J Roentgenol* 159:757-61, 10/1992.
23. Fuhrman, Hohn DC, **Curley SA**. High-dose hepatic arterial Adriamycin with systemic protection provided by a novel hepatic venous isolation catheter and extracorporeal chemofiltration. *Surg Forum* 43:440-442, 1992.
24. Charnsangavej C, Kirk IR, Dubrow RA, Chuang VP, **Curley SA**, Roh MS, Varma DG, Patt YZ. Arterial complications from long-term hepatic artery chemoinfusion catheters: evaluation with CT. *AJR Am J Roentgenol* 160:859-64, 4/1993.
25. Podoloff DA, Patt YZ, **Curley SA**, Kim EE, Bhadkamkar VA, Smith RE. Imaging of colorectal carcinoma with technetium-99m radiolabeled Fab' fragments. *Semin Nucl Med* 23:89-98, 4/1993.
26. Carlson GW, **Curley SA**, Martin JE, Fornage BD, Ames FC. The detection of breast cancer after augmentation mammoplasty. *Plast Reconstr Surg* 91:837-840, 4/1993.

27. **Curley SA**, Roh MS, Feig B, Oyedeji C, Kleinerman ES, Klostergaard J. Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26. *J Leukoc Biol* 53:715-721, 6/1993.
28. Patt YZ, Podoloff DA, **Curley SA**, Smith R, Badkhamkar VA, Lamki LM, Jessup MM, Hohn DC. Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen. Experience with ZCE-025 and IMMU-4 monoclonal antibodies and proposed directions for clinical trials. *Cancer* 71:4293-4297, 6/1993.
29. McDaniel KP, Charnsangavej C, DuBrow RA, Varma DG, Granfield CA, **Curley SA**. Pathways of nodal metastasis in carcinomas of the cecum, ascending colon, and transverse colon: CT demonstration. *AJR Am J Roentgenol* 161:61-64, 7/1993.
30. **Curley SA**, Byrd DR, Newman RA, Ellis HJ, Chase J, Carrasco CH, Cleary K, Bodden W, Hohn DC. Reduction of systemic drug exposure after hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration. *Surgery* 114:579-585, 9/1993.
31. Talamonti MS, Shumate CR, Carlson GW, **Curley SA**. Locally advanced carcinoma of the colon and rectum involving the urinary bladder. *Surg Gynecol Obstet* 177:481-487, 11/1993.
32. **Curley SA**, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. *Surgery* 114:928-935, 11/1993.
33. **Curley SA**, Roh MS, Chase JL, Hohn DC. Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. *Am J Surg* 166:743-746; discussion 746-8, 12/1993.
34. Teeter LD, Hsu HC, **Curley SA**, Tong MJ, Kuo MT. Expression of multidrug resistance (P-glycoprotein) MDR1 and MDR2 genes in human hepatocellular carcinomas and liver metastases of colonic tumor. *Int J Cancer* 2:73-80, 1993.
35. Talamonti MS, Roh MS, **Curley SA**, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. *J Clin Invest* 91:53-60, 1993.
36. **Curley SA**, Stone DL, Fuhrman GM, Hohn DC, Siddik ZH, Newman RA. Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration. *Cancer Chemother Pharmacol* 33:251-257, 1993.
37. Murray JL, Rosenblum MG, Zhang HZ, Podoloff DA, Kasi LP, **Curley SA**, Chan JC, Roh M, Hohn DC, Brewer H, Cunningham JE, Thompson LB, Bhadkamkar V, Pinsky C, Fogler WE. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')₂ in colorectal cancer patients. *Cancer* 73:850-857, 2/1994.
38. Fuhrman GM, Cromeens DM, Newman RA, Cleary KR, Carrasco CH, Wright KC, Guercio S, Guercio A, **Curley SA**. Hepatic arterial infusion of verapamil and doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration: pharmacological evaluation of

reduction in systemic drug exposure and assessment of hepatic toxicity. *Surg Oncol* 3:17-25, 2/1994.

39. **Curley SA**, Newman RA, Dougherty TB, Fuhrman GM, Stone DL, Mikolajek JA, Guercio S, Guercio A, Carrasco CH, Kuo MT, Hohn DC. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. *Ann Surg Oncol* 1:389-399, 9/1994.
40. **Curley SA**, Evans DB, Ames FC. Resection for cure of carcinoma of the colon directly invading the duodenum or pancreatic head. *J Am Coll Surg* 179:587-592, 11/1994.
41. Rich TA, Evans DB, **Curley SA**, Ajani JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. *Ann Oncol* 5 Suppl 3:75-80, 1994.
42. Davidson BS, Fuhrman GM, Siddik ZH, **Curley SA**. Matrix therapeutic implant increases intratumoral cisplatin levels and enhances tumoricidal activity. *Surg Forum* 45:466-468, 1994.
43. Barnes G, Jr, Romero L, Hess KR, **Curley SA**. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. *Ann Surg Oncol* 1:73-78, 1994.
44. Patt YZ, Podoloff D, **Curley SA**, Kasi L, Smith R, Bhadkamkar V, Charnsangavej C. Technetium 99m labeled MoAb anti-carcinoembryonic antigen (CEA) IMMU-4 for imaging of occult recurrent colorectal cancer in patients with rising serum CEA. *J Clin Oncol* 12:489-495, 1994.
45. Pollock RE, **Curley SA**, Lotzova E. Ethics of research training for NIH T32 surgical investigators. *J Surg Res* 58:247-251, 2/1995.
46. Davidson BS, Izzo F, Cromeens DM, Stephens LC, Siddik ZH, **Curley SA**. Collagen matrix cisplatin prevents local tumor growth after margin-positive resection. *J Surg Res* 58:618-624, 6/1995.
47. DuBrow RA, David CL, **Curley SA**. Anastomotic leaks after low anterior resection for rectal carcinoma: evaluation with CT and barium enema. *AJR Am J Roentgenol* 165:5675-71, 9/1995.
48. **Curley SA**, Izzo F, Gallipoli A, de Bellis M, Cremona F, Parisi V. Identification and screening of 416 patients with chronic hepatitis at high risk of developing hepatocellular cancer. *Ann Surg* 222:375-380; discussion 380-383, 9/1995.
49. Berger DH, Carrasco CH, Hohn DC, **Curley SA**. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. *J Surg Oncol* 60:116-121, 10/1995.
50. Fuhrman GM, **Curley SA**, Hohn DC, Roh MS. Improved survival after resection of colorectal liver metastases. *Ann Surg Oncol* 2:537-541, 11/1995.
51. **Curley SA**, Fuhrman GM, Siddik ZH, Davidson BS, Cleary KR, Cromeens DM. Direct intratumoral injection of a novel collagen matrix gel and cisplatin effectively controls experimental liver tumors. *Cancer Res Therapy and Control* 4:247-254, 1995.
52. Lowy AM, Rich TA, Skibber JM, Dubrow RA, **Curley SA**. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. *Ann Surg* 223:177-185, 2/1996.

53. Izzo F, **Curley SA**, Maio P, Leonardi E, Imparato L, Giglio S, Cremona F, Castello G. Correlation of soluble interleukin-2 receptor levels with severity of chronic hepatitis C virus liver injury and development of hepatocellular cancer. *Surgery* 120:100-105, 7/1996.
54. Lee JE, Lowy AM, Thompson WA, Lu M, Loflin PT, Skibber JM, Evans DB, **Curley SA**, Mansfield PF, Reville JD. Association of gastric adenocarcinoma with the HLA class II gene DQB10301. *Gastroenterology* 111:426-432, 8/1996.
55. Han NM, **Curley SA**, Gallick GE. Differential activation of pp60(c-src) and pp62(cyes) in human colorectal carcinoma liver metastases. *Clin Cancer Res* 2:1397-1404, 8/1996.
56. Kuo MT, Bao JJ, **Curley SA**, Ikeguchi M, Johnston DA, Ishikawa T. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. *Cancer Res* 56:3642-3644, 8/1996.
57. Cusack JC, Giacco GG, Cleary K, Davidson BS, Izzo F, Skibber J, Yen J, **Curley SA**. Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma. *J Am Coll Surg* 183:105-112, 8/1996.
58. Davidson BS, Izzo F, Chase JL, DuBrow RA, Patt Y, Hohn DC, **Curley SA**. Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. *Am J Surg* 172:244-247, 9/1996.
59. Lee JE, **Curley SA**, Gagel RF, Evans DB, Hickey RC. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. *Surgery* 120:1064-1070; discussion 1070-1071, 12/1996.
60. Jones DV, Chase J, Roh M, Hohn DC, **Curley SA**, Smith R, Hoque A, Patt YZ. A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer. *Oncol Reports* 3:391-395, 1996.
61. Balch G, Izzo F, Chiao P, Klostergaard J, **Curley SA**. Activation of human Kupffer cells by thymostimulin (TP-1) to produce cytotoxicity against human hepatocellular cancer. *Ann Surg Oncol* 4:149-155, 3/1997.
62. Tuttle TM, **Curley SA**, Roh MS. Repeat hepatic resection as effective treatment of recurrent colorectal liver metastases. *Ann Surg Oncol* 4:125-130, 3/1997.
63. Koura AN, Giacco GG, **Curley SA**, Skibber JM, Feig BW, Ellis LM. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. *Cancer* 79:1294-1298, 4/1997.
64. Han NM, Fleming RY, **Curley SA**, Gallick GE. Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation. *Ann Surg Oncol* 4:264-268, 4/1997.
65. Patt YZ, Hoque A, Lozano R, Pozdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, **Curley SA**, Roh M, Jones DV, Jr. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. *J Clin Oncol* 15:1432-1438, 4/1997.
66. Dougherty TB, Mikolajek JA, **Curley SA**. Safe anesthetic management of patients undergoing a novel method of treating human hepatocellular cancer. *J Clin Anesth* 9:220-227, 5/1997.

67. **Curley SA**, Davidson BS, Fleming RY, Izzo F, Stephens LC, Tinkey P, Cromeens D. Laparoscopically guided bipolar radiofrequency ablation of areas of porcine liver. *Surg Endosc* 11:729-733, 7/1997.
68. Ricardo AE, Feig BW, Ellis LM, Hunt KK, **Curley SA**, MacFadyen BV, Jr, Mansfield PF. Gallbladder cancer and trocar site recurrences. *Am J Surg* 174:619-622; discussion 622-623, 12/1997.
69. McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, **Curley SA**. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. *Am J Surg* 174:605-608; discussion 608-609, 12/1997.
70. Miller AR, Cantor SB, Peoples GE, Pearlstone DB, **Curley SA**, Skibber JM. Costeffectiveness and outcomes of therapy for recurrent rectal cancer. *Surg Forum* 48:234-236, 1997.
71. Izzo F, Di Muria A, Ruffolo F, Parisi V, **Curley SA**. Intraoperative use of radiofrequency interstitial tissue ablation to treat primary and metastatic liver tumors. *Gastroenterology International* 10:515-516, 1997.
72. Izzo F, Ruffolo F, Di Muria A, De Angelis P, Parisi V, **Curley SA**. Radiofrequency interstitial tissue ablation to treat primary and metastatic liver tumors. *J Exp Clin Cancer Res* 16:330-332, 1997.
73. **Curley SA**, Lott ST, Luca JW, Frazier ML, Killary AM. Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. *Ann Surg* 227:229-235, 2/1998.
74. Izzo F, Cremona F, Ruffolo F, Palaia R, Parisi V, **Curley SA**. Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. *Ann Surg* 227:513-518, 4/1998.
75. Bouvet M, Staerkel GA, Spitz FR, **Curley SA**, Charnsangavej C, Hagemeister FB, Janjan NA, Pisters PW, Evans DB. Primary pancreatic lymphoma. *Surgery* 123:382-390, 4/1998.
76. Bouvet M, Mansfield PF, Skibber JM, **Curley SA**, Ellis LM, Giacco GG, Madary AR, Ota DM, Feig BW. Clinical, pathologic, and economic parameters of laparoscopic colon resection for cancer. *Am J Surg* 176:554-558, 12/1998.
77. Leach SD, Davidson BS, Berger DH, **Curley SA**, Tainsky MA. Enhanced Krev-1 expression inhibits the growth of pancreatic adenocarcinoma cells. *Pancreas* 16:491-498, 1998.
78. Izzo F, Cremona F, Delrio P, Leonardi E, Castello G, Pignata S, Daniele B, **Curley SA**. Soluble interleukin-2 receptor levels in hepatocellular cancer: a more sensitive marker than alpha fetoprotein. *Ann Surg Oncol* 6:178-185, 3/1999.
79. **Curley SA**, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. *Ann Surg* 230:1-8, 7/1999.
80. Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS, Granchi J, **Curley SA**. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. *Am J Surg* 178:592-599, 12/1999.

81. Janjan N, Waugh K, Skibber JM, **Curley SA**, Lawrence D, Richli R, Thomas J, Berner P, Lawyer A, Horton JL. Control of unresectable recurrent anorectal cancer with Au198 seed implantation. *J Brachytherapy International* 15:115-129, 1999.
82. Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, **Curley SA**, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. *J Clin Oncol* 17:2403-2411, 1999.
83. Pearlstone DB, Mansfield PF, **Curley SA**, Kumparatana M, Cook P, Feig BW. Laparoscopy in 533 patients with abdominal malignancy. *Surgery* 125:67-72, 1999.
84. **Curley SA**, Izzo F. Laparoscopic radiofrequency. *Ann Surg Oncol* 7:78-79, 2000.
85. Janjan, Crane CH, Feig BW, Cleary K, Dubrow R, **Curley SA**, Ellis LM, Vauthey JN, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys* 47:713-718, 2000.
86. **Curley SA**, Izzo F, Ellis LM, Vauthey JN, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 cirrhotic patients. *Ann Surg* 232:381-391, 2000.
87. Meric F, Patt YZ, **Curley SA**, Chase J, Roh MS, Vauthey JN, Ellis LM. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. *Ann Surg Oncol* 7:490-495, 2000.
88. Ahmad SA, Bilimoria MM, Wang X, Izzo F, Delrio P, Marra P, Baker TP, Porter GA, Ellis LM, Vauthey JN, Dhamotharan S, **Curley SA**. Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma. *J Gastrointest Surg* 5:468-476, 9/2001.
89. Choi H, Loyer EM, DuBrow RA, Kaur H, David CL, Huang S, **Curley SA**, Charnsangavej C. Radio-frequency ablation of liver tumors: assessment of therapeutic response and complications. *Radiographics* 21 Spec No: S41-54, 10/2001.
90. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, **Curley SA**, Schnirer, II, Raijman I. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. *Clin Cancer Res* 7:3375-3380, 11/2001.
91. Lenert JT, Barnett CC, Jr, Kudelka AP, Sellin RV, Gagel RF, Prieto VG, Skibber JM, Ross MI, Pisters PW, **Curley SA**, Evans DB, Lee JE. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. *Surgery* 130:1060-1067, 12/2001.
92. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, **Curley SA**, Stephens LC, Fang B. Antitumor activity, and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. *Cancer Res* 61:3330-3338, 2001.
93. Barnett CC, Moore EE, Silliman CC, Abdalla EK, Partrick DA, **Curley SA**. Cytosolic Phospholipase A2 mediated ICAM-1 expression is calcium dependent. *J Surg Res* 99:307-310, 2001.
94. **Curley SA**. Dialogues in Oncology. Radiofrequency ablation of malignant liver tumors. *The Oncologist* 6:14-23, 2001.

95. Crane C, Janjan NA, Abbruzzese JL, **Curley S**, Vauthey J-N, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, Wolff RA, Lenzi R, Brown TD, Lynch P, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. *Int J Radiat Oncol Biol Phys* 49:107-116, 2001.
96. Janjan N, Crane C, Feig BW, Cleary K, Dubrow R, **Curley SA**, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. *Am J Clin Oncol* 24:107-112, 2001.
97. Izzo F, Thomas R, Delrio P, Rinaldo M, Vallone P, DeChiara A, Botti G, D'Aiuto G, Cortino P, **Curley SA**. Radiofrequency ablation of primary breast cancer: A pilot study in 26 patients. *Cancer* 92:2036-3044, 2001.
98. Sanfilippo NJ, Crane CH, Skibber J, Feig B, Abbruzzese JL, **Curley SA**, Vauthey J-N, Ellis LM, Hoff P, Wolff RA, Brown TD, Cleary K, Wong A, Phan T, Janjan NA. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: Patterns of failure and limitations of treatment. *Int J Radiation Oncology Biol Phys* 51:176-183, 2001.
99. Bilimoria MM, Lauwers GY, Doherty DA, Nagorney DM, Belghiti J, Do KA, Regimbeau JM, Ellis LM, **Curley SA**, Ikai I, Yamaoka Y, Vauthey JN. Underlying liver disease, not tumor factors, predicts long-term survival after hepatic resection of hepatocellular carcinoma. *Arch Surg* 136:528-535, 2001.
100. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, **Curley SA**, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. *Cancer* 94:344-351, 1/2002.
101. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, **Curley SA**, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM. Simplified staging for hepatocellular carcinoma. *J Clin Oncol* 20:1527-1536, 3/2002.
102. Lott ST, Chandler DS, **Curley SA**, Foster CJ, El-Naggar A, Frazier M, Strong LC, Lovell M, Killary AM. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. *Cancer Res* 62:1952-1955, 4/2002.
103. Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, **Curley SA**, Pollock RE, Vauthey JN. Preoperative predictors of survival after resection of small hepatocellular carcinomas. *Ann Surg* 235:722-730; discussion 730-731, 5/2002.
104. Lin-Lee YC, Nakamura S, Gandhi V, **Curley SA**, Stuber D, Burkot TR, Kuo MT. Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells. *Mol Cancer Ther* 1:461-467, 5/2002.

105. Abdalla EK, Barnett CC, Doherty D, **Curley SA**, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. *Arch Surg* 137:675-680; discussion 680-681, 6/2002.
106. Lin T, Gu J, Zhang L, Huang X, Stephens LC, **Curley SA**, Fang B. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. *Cancer Res* 62:3620-3625, 7/2002.
107. Crane CH, Macdonald OK, Vauthey JN, Patt Y, Brown T, **Curley S**, Wong A, Declos M, Charnsangavej C, Janjan, NA. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. *Int J Radiat Oncol Biol Physics* 53:969-974, 2002.
108. Lin E, Huang X, Gu J, Zhang L, Roth JA, Xiong M, **Curley SA**, Yu Y, Hunt KK, Fang B. Long-term tumor-free survival from treatment with GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. *Oncogene* 21:8020-8028, 2002.
109. Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR, **Curley SA**, Crane CH, Cleeland CS, Janjan NA, Skibber JM. Pain and quality of life after treatment in patients with locally recurrent rectal cancer. *J Clin Oncol* 20:4361-4367, 2002.
110. **Curley SA**, Izzo F. Radiofrequency ablation of primary and metastatic liver tumors. *Surg Technol Int* 10:99-106, 2002.
111. Chiao P, Na R, Niu J, Sclabas GM, Dong Q, **Curley SA**. Role of Rel/NF-6B transcription factors in apoptosis of human hepatocellular carcinoma cells. *Cancer* 5:1696-1705, 2002.
112. Singletary SE, Walsh G, Vauthey JN, **Curley SA**, Sawaya R, Weber KL, Meric F, Hortobagyi GN. The role of curative surgery in the treatment of selected patients with metastatic breast cancer. *The Oncologist* 8:241-251, 2003.
113. Pawlik TN, Izzo F, **Curley SA**. Combined resection and radiofrequency ablation for advanced hepatic malignancies: Results in 172 patients. *Ann Surg Oncol* 10:1059-1069, 2003.
114. Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J, Yamaoka Y, **Curley SA**, Ellis LM, Nagorney DM, Vauthey JN. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. *Annals of Surgery* 238:711-719, 2003.
115. Scaife CL, **Curley SA**, Izzo F, Marra P, Delrio P, Daniele B, Cremona F, Gershenwald JE, Chase JL, Lozano RD, Patt YS, Fornage BD, Vauthey JN, Woodall ML, Gonzalez KB, Ellis LM. Feasibility of adjuvant hepatic arterial infusion (HAI) of chemotherapy following radiofrequency ablation (RFA) +/- resection in patients with hepatic metastasis from colorectal cancer. *Ann Surg Oncol* 10:348-354, 2003.
116. Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, **Curley SA**, Wong A, Delclos M, Charnsangavej C, Janjan NA. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. *Int J Radiat Oncol Biol Phys* 53:969-974, 2003.

117. Parikh AA, Gentner B, Wu T-T, **Curley SA**, Ellis LM, Vauthey J-N. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. *J Gastrointest Surg* 7(1082-1088), 2003.
118. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, **Curley SA**, Ellis LM. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alpha-2b for treatment of hepatocellular carcinoma. *J Clin Oncol* 21:4214-27, 2003.
119. **Curley SA**, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA. Regression of hepatocellular cancer in a patient treated with arginine deiminase. *HepatoGastroenterology* 50:1208-1211, 2003.
120. Crane C, Skibber J, Feig B, Vauthey J-N, Thames H, **Curley SA**, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Declos M, Lin E, Janjan NA. Response to preoperative chemoradiation increases the use of sphincter preserving surgery in locally advanced low rectal cancer. *Cancer* 97:517-524, 2003.
121. **Curley SA**, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife C, Raut C, Wolff R, Choi H, Loyer E, Vallone P, Fiore F, Scordino F, De Rosa V, Orlando R, Pignata S, Daniele B, Izzo F. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. *Ann Surg* 239:450-458, 4/2004.
122. Patten LC, Berger DH, Rodriguez-Bigas M, Mansfield P, Delpassand E, Cleary KR, Fagan SP, **Curley SA**, Hunt KK, Feig BW. A prospective evaluation of radiocolloid and immunohistochemical staining in colon carcinoma lymphatic mapping. *Cancer* 100:2104-2109, 5/2004.
123. Vauthey JN, Pawlik TM, Abdalla EK, Arens JF, Nemr RA, Wei SH, Kenamer DL, Ellis LM, **Curley SA**. Is extended hepatectomy for hepatobiliary malignancy justified? *Ann Surg* 239:722-730; discussion 730-732, 5/2004.
124. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, **Curley SA**. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. *J Clin Oncol* 22:1815-1822, 5/2004.
125. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, **Curley SA**. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. *Ann Surg* 239:818-825; discussion 825-827, 6/2004.
126. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, **Curley SA**, Vauthey JN, Ellis LM, Schnirer, II, Wolff RA, Charnsangavej C, Brown TD. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. *Cancer* 101:578-586, 8/2004.
127. Vlastos G, Smith DL, Singletary SE, Mirza NQ, Tuttle TM, Popat RJ, **Curley SA**, Ellis LM, Roh MS, Vauthey JN. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. *Ann Surg Oncol* 11:869-874, 9/2004.

128. Pawlik TM, Poon RT, Abdalla EK, Ikai I, **Curley SA**, Nagorney DM, Belghiti J, Ng IO-L, Yamaoka Y, Lauwers GY, Vauthey J-N. Hepatitis Serology Predicts Tumor and Liver-Disease Characteristics but not Prognosis after Resection of Hepatocellular Carcinoma. *J Gastro Surg* 8:794-804, 2004.
129. Dillon BJ, Prieto VG, **Curley SA**, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: A method for identifying cancer sensitive to arginine deprivation. *Cancer* 100:826-833, 2004.
130. Bedrosian I, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, **Curley SA**, Vauthey JN, Declos M, Crane C, Janjan N, Skibber JM. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. *J. Gastro Surg* 8:56-63, 2004.
131. Mullen JT, Walsh GL, Abdalla EK, Loyer EM, **Curley SA**, Vauthey J-N. Transdiaphragmatic Radiofrequency Ablation of Liver Tumors. *J Amer Coll Surg* 199(826-829), 2004.
132. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, **Curley SA**, Yamaoka Y, Lauwers GY, Vauthey JN. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. *Surgery* 137:403-410, 4/2005.
133. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, **Curley SA**, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. *Ann Surg* 241:715-722, discussion 722-724, 5/2005.
134. Smith DL, Arens JF, Barnett CC, Jr, Izzo F, **Curley SA**. A prospective evaluation of ultrasound-directed transparenchymal vascular control with linear cutting staplers in major hepatic resections. *Am J Surg* 190:23-29, 7/2005.
135. Raut CP, Izzo F, Marra P, Ellis LM, Vauthey JN, Cremona F, Vallone P, Mastro A, Fornage BD, **Curley SA**. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. *Ann Surg Oncol* 12:616-628, 8/2005.
136. Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, **Curley SA**. Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. *Clin Radiol* 60(6):700-709, 2005.
137. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, **Curley SA**, Nagorney DM, Belghiti J, Ng IO, Yamaoka Y, Lauwers GY, Vauthey JN. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. *Arch Surg* 140(5):450-457, 2005.
138. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, **Curley SA**, Nagorney DM, Ng IO, Fan ST, Poon RT. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. *Ann Surg Oncol* 12(5):364-373, 2005.
139. Bilchik AJ, Poston G, **Curley SA**, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P, Rosen LS. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. *J Clin Oncol* 23:9073-9078, 2005.
140. Poston GJ, Adam R, Alberts S, **Curley SA**, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey J-N,

Cornelis M, Kahan JP. OncoSurge: A strategy for improving resectability with curative intent in metastatic colorectal cancer. *J Clin Oncol* 23(28):7125-7134, 2005.

141. Ellis LM, **Curley SA**, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. *J Clin Oncol* 23(22):4853-4855, 2005.
142. Pawlik TM, Delman KA, Vauthey J-N, Nagorney DM, Ng, IO-L, Ikai I, Yamaoka Y, **Curley SA**, Belghiti J, Poon R, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: Implications for expecting the criteria for hepatic transplantation. *Liver Transplantation* 11:1086-1092, 2005.
143. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, **Curley SA**, Mentha G, Capussotti L, Vauthey JN. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. *J Gastrointest Surg* 10:86-94, 1/2006.
144. Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, **Curley SA**. Debunking dogma: surgery for four or more colorectal liver metastases is justified. *J Gastrointest Surg* 10:240-248, 2/2006.
145. Bedrosian I, Giacco G, Pederson L, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, **Curley SA**, Vauthey JN, Delclos M, Crane CH, Janjan N, Skibber JM. Outcome after curative resection for locally recurrent rectal cancer. *Dis Colon Rectum* 49:175-182, 2/2006.
146. Scaife CL, Ng CS, Ellis LM, Vauthey JN, Charnsangavej C, **Curley SA**. Accuracy of preoperative imaging of hepatic tumors with helical computed tomography. *Ann Surg Oncol* 13:542-546, 4/2006.
147. Delman KA, Shapiro SE, Jonasch EW, Lee JE, **Curley SA**, Evans DB, Perrier ND. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. *World J Surg* 30:665-669, 5/2006.
148. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, **Curley SA**, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. *J Clin Oncol* 24:2065-2072, 5/2006.
149. Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Aloia TA, **Curley SA**, Camacho LH, Capussotti L, Elias D, Vauthey JN. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. *Ann Surg Oncol* 13:712-720, 5/2006.
150. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, **Curley SA**, Zorzi D, Abdalla EK. Solitary colorectal liver metastasis: resection determines outcome. *Arch Surg* 141:460-466; discussion 466-467, 5/2006.
151. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, **Curley SA**. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. *Arch Surg* 141:537-543; discussion 543-544, 6/2006.
152. Lin EH, **Curley SA**, Crane CC, Feig B, Skibber J, Delcos M, Vadhan SR, Morris J, Ayers GD, Ross A, Brown T, Rodriguez-Bigas MA, Janjan N. Retrospective study of capecitabine and celecoxib in

metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities, and survival? *Am J Clin Oncol* 29:232-239, 6/2006.

153. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Hamilton SR, Ellis LM, **Curley SA**, Abdalla EK, Vauthey J-N. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. *Cancer* 110:2761-2767, 2007.
154. Gannon CJ, Cherukuri P, Yakobson BI, Cognet L, Kanzius JS, Kittrell C, Weisman RB, Pasquali M, Schmidt HI, Smalley RE, **Curley SA**. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. *Cancer* 110:2654-2665, 2007.
155. Kodama Y, Ng CS, Wu TT, Ayers GD, **Curley SA**, Abdalla EK, Vauthey JN, Charnsangavej C. Comparison of CT methods for determining the fat content of the liver. *Am J Roentgenol* 188:1307-1312, 2007.
156. Hayes-Jordan A, Anderson P, **Curley S**, Herzog C, Lally KP, Green HL, Hunt K, Mansfield P. Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor. *J Ped Surg* 42:29-32, 2007.
157. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi D, Gautam S, Abdalla EK, **Curley SA**, Capussotti L, Clary BM, Vauthey J-N. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. *J Am Coll Surg* 204:854-864, 2007.
158. Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN, **Curley SA**. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. *Am J Surg* 193:702-706, 2007.
159. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, **Curley SA**, Choti MA, Elias D. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: Results of a multi-center analysis. *Ann Surg Oncol*, 2007.
160. Cherukuri P, Gannon CJ, Leeuw TK, Schmidt HK, Smalley RE, **Curley SA**, Weisman RB. Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescence. *Proc Natl Acad Sci* 103:18882-18886, 2007.
161. Izzo F, Montella M, Pio Orlando A, Nasti G, Beneduce G, Castello G, Cremona F, Ensor CM, Holtzberg FW, Bomalaski JS, Clark MA, **Curley SA**, Orlando R, Scordino F, Korba BE. Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. *J Gastroenterol Hepatol* 22:86-91, 2007.
162. Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, **Curley SA**, Hortobagyi GN, Mavligit G. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. *Cancer* 109:2190-2196, 2007.
163. Abdalla EK, Ribero D, Pawlik TM, Zorzi D, **Curley SA**, Muratore A, Andres A, Metha G, Capussotti L, Vauthey J-N. Resection of hepatic colorectal metastases involving the caudate lobe: Perioperative outcome and survival. *J Gastrointest Surg* 11:66-72, 2007.

164. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, **Curley SA**, Abdalla EK. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. *J Gastrointest Surg* 11:1498-1504, 2007.
165. Vauthey JN, Palavecino M, **Curley SA**, Abdalla EK. Re: Right hepatic trisectionectomy for hepatobiliary disease: results and an appraisal of its current role. *Ann Surg* 248(1):138-9; author reply 139-40, 7/2008.
166. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, **Curley S**, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: Patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. *Ann Surg Oncol* 15(11):3147-3156, 8/2008.
167. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, **Curley SA**, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. *Int J Cancer* 123:1883-1891, 2008.
168. Izzo F, Di Giacomo R, Falco P, Piccirillo M, Iodice R, Orlando AP, Aprea P, Cremona F, Di Marzo M, Idà DN, Mastro AA, **Curley SA**. Efficacy of a haemostatic matrix for the management of bleeding in patients undergoing liver resection: results from 237 cases. *Curr Med Res Opin* 24(4):1011-5, 2008.
169. Gannon CJ, Patra CR, Bhattacharya R, Mukherjee P, **Curley SA**. Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. *J Nanobiotechnology* 6:2, 2008.
170. **Curley SA**, Cherukuri P, Briggs K, Patra CR, Upton M, Dolson E, Mukherjee P. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. *J Exp Ther Oncol* 7:313-326, 2008.
171. Blazer DG, 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, **Curley SA**, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. *J Clin Oncol* 26(33):5344-5351, 2008.
172. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, **Curley SA**, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. *J Clin Oncol* 26(32):5254-5260, 2008.
173. Ribero D, **Curley SA**, Imamura H, Madoff DC, Nagorney DM, Ng KK, Donadon M, Vilgrain V, Torzilli G, Roh M, Vauthey JN. Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. *Ann Surg Oncol* 15(4):986-992, 2008.

174. Hassan MM, Li D, Patt YZ, Vauthey J-N, Thomas MB, **Curley SA**, Abdalla EK, Davila M, Spitz MR, Lozano RD, Hassan DM, El-Deeb AS, Chan W, Kaseb A, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: USA case-control study. *Hepatology* 49:1563-1570, 2009.
175. Chun YS, Vauthey J-N, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, **Curley SA**, Abdalla EK, Kaur H, Charnsangavej C, Loyer EM. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. *JAMA* 302:2338-2344, 2009.
176. Gannon CJ, Izzo F, Aloia TA, Pignata S, Nasti G, Vallone P, Orlando R, Scordino F, **Curley SA**. Can screening for hepatocellular cancer increase the proportion of longterm survivors? *Hepatogastroenterology* 56(93):1152-1156, 2009.
177. Badgwell BD, Smith K, Liu P, Bruera E, **Curley SA**, Cormier JN. Indicators of surgery and survival in oncology inpatients requiring surgical evaluation for palliation. *Support Care Cancer* 17:727-734, 2009.
178. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, **Curley SA**, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. *Surgery* 145(4):399-405, 2009.
179. Moran CH, Wainerdi SM, Cherukuri TK, Kittrell C, Wiley BJ, Nicholas NW, **Curley SA**, Kanzius JS, Cherukuri PC. Size dependent joule heating of gold nanoparticles using capacitively coupled radiofrequency fields. *Nano Res* 2:400-405, 2009.
180. Hassan MM, Spitz MR, Thomas MB, **Curley SA**, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. *J Hepatol* 50(2):334-341, 2009.
181. Kishi, Y, Abdalla, EK, Chun, YS, Zorzi, D, Madoff, DC, Wallace, MJ, **Curley, SA**, Vauthey, JN. Three Hundred and One Consecutive Extended Right Hepatectomies: Evaluation of Outcome Based on Systematic Liver Volumetry. *Ann Surg.* e-Pub 2009.
182. Stone EM, Glazer ES, Chantarnupong L, Cherukuri P, Breece RM, Tierney DL, **Curley SA**, Iverson BL, Georgiou G. Replacing Mn (2+) with Co (2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines. *ACS Chem Biol* 5(3):333-42, 3/2010. PMID: PMC2842482.
183. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, **Curley SA**. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. *Arch Surg* 145(4):340-5; discussion 345, 4/2010.
184. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, **Curley SA**, Izzo F. Phase II study of pegylated arginine deiminase for non-resectable and metastatic hepatocellular carcinoma. *J Clin Oncol* 28(13):2220-2226, 5/2010. e-Pub 3/2010.

185. Glazer ES, **Curley SA**. Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles. *Cancer*. 2010 Jul 1;116(13):3285-93, doi: 10.1002/cncr.25135. PMID 20564640.
186. Glazer ES, Kaluarachchi WD, Massey KL, Zhu C, **Curley SA**. Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1. *Surgery* 148(2):310-8, 8/2010. e-Pub 5/2010. PMCID: PMC2905509.
187. Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, **Curley SA**. Long-term survival after surgical management of neuroendocrine hepatic metastases. *HPB (Oxford)*. 2010 Aug;12(6):427-33, doi: 10.1111/j.1477-2574.2010.00198.x. PMID: 20662794.
188. Glazer ES, Massey KL, Zhu C, **Curley SA**. Pancreatic carcinoma cells are susceptible to non-invasive radiofrequency fields after treatment with targeted gold nanoparticles. *Surgery* 2(319):324, 8/2010. e-Pub 6/2010. PMCID: PMC2904623.
189. Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, **Curley SA**. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. *Clin Cancer Res*. 2010 Dec 1;16(23):5712-21, doi: 10.1158/1078-0432.CCR-10-2055. PMID: 21138869.
190. Glazer ES, Massey KL, **Curley SA**. A protocol to effectively create single cell suspensions of adherent cells for multiparameter high throughput flow cytometry. *In Vitro Cell Dev Biol Anim* 46:97-101, 2010.
191. Hassan M, **Curley SA**, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey J-N. Association of diabetes duration and diabetes treatment with the risk of hepatocellular cancer. *Cancer* 116:1938-1946, 2010.
192. Kishi Y, Zorzi D, Maru DM, Kopetz S, Ribero D, Motta M, Ravarino N, Risio M, **Curley SA**, Abdalla EK, Capussotti L, Vauthey JN. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. *Ann Surg Oncol*. 2010 Nov;17(11):2870-76, doi: 10.1245/s10434-010-1166-1. Epub 2010 Jun 22. PMID: 20567921.
193. Castello, G, Scala, S, Palmieri, G, **Curley, SA**, Izzo, F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. *Clin Immunol* 134:237-250, 2010.
194. Thomas MB, Jaffe D, Choti M, Belghiti J, **Curley SA**, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. *J Clin Oncol*. 2010 Sep 1;28(25):3994-4005, doi: 10.1200/JCO.2010.28.7805. Epub 2010 Aug 2. Erratum in: *J Clin Oncol*. 2010 Dec 20;28(36):5350. PMID: 20679622.
195. Bhattacharyya S, Battacharya R, **Curley SA**, McNiven M, Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. *Proc Natl Acad Sci U S A*. 2010 Aug 17; 107:14541-6, doi: 10.1073/pnas.1006507107. Epub 2010 Aug 2. PMID: 20679244.

196. Brouquet A, Mortenson MM, Vauthey J-N, Rodriguez-Bigas MA, Skibber JM, Chang GJ, Overman MJ, Kopetz SE, Garrett C, Chun Y-S, **Curley SA**, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 172 consecutive patients: Classic, combined, or reverse approach? *J Am Coll Surgeons* 210:934-941, 2010.
197. Cherukuri, P, Glazer, ES, **Curley, SA**. Targeted hyperthermia using metal nanoparticles. *Adv Drug Deliv Rev* 62:339-345, 2010.
198. Palavecino, M, Kishi, Y, Chun, YS, Brown, DL, Gottumukkala, VN, Lichtiger, B, **Curley, SA**, Abdalla, EK, Vauthey, JN. Two-surgeon technique of parenchymal transection contributes to reduced transfusion rate in patients undergoing major hepatectomy: Analysis of 1,557 consecutive liver resections. *Surgery* 147:40-48, 2010.
199. Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, **Curley SA**. Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. *Transl Oncol*. 2011 Jun;4(3):138-46, Epub 2011 Jun 1. PMID: 21633669.
200. Glazer ES, Zhu C, Hamir AN, Borne A, Thompson CS, **Curley SA**. Biodistribution and acute toxicity of naked gold nanoparticles in a rabbit hepatic tumor model. *Nanotoxicology*. 2011 Dec;5(4):459-68, doi: 10.3109/17435390.2010.516026. Epub 2010 Sep 21. PMID: 20854190.
201. Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, **Curley SA**, Ellis LM, DuBois RN, Hung MC. APOBEC3G promotes liver metastasis in orthotopic colorectal cancer mouse model and predicts human hepatic metastasis. *J Clin Invest*. 2011 Nov;121(11):4526-36, doi: 10.1172/JCI45008. Epub 2011 Oct 10. PMID: 21985787.
202. Khan JA, Kudgus RA, Szabolcs A, Dutta S, Wang E, Cao S, Curran GL, Shah V, **Curley SA**, Mukhopadhyay D, Robertson JD, Bhattacharya R, Mukherjee P. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. *PLoS One*. 2011;6(6): e20347, doi: 10.1371/journal.pone.0020347. Epub 2011 Jun 27. PMID: 21738572.
203. Ding Q, Chang C-J, Xie X, Xia W, Yang J-Y, Wang S-C, Wang Y, Xia J, Cheng L, Cai C, Li H, Yen C-J, Kuo H-P, Lee D-F, Lang J, Huo L, Cheng X, Chen Y-J, Li CW, Jeng L-B, Li L-Y, **Curley SA**, Dubois RN, Hung M-C. Genes that mediate colorectal cancer metastasis to liver. *J Clin Invest*. e-Pub 2011.
204. Brouquet A, Vauthey J-N, Badgwell BD, Ribero D, **Curley SA**, Abdalla EK. Hepatectomy for recurrent colorectal liver metastases after initial treatment with radiofrequency ablation or resection: Resection first defines outcome. *Br J Surg* 98:1003-1009, 2011.
205. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Loyer EM, Madoff DC, **Curley SA**, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. *J Clin Oncol*. 2011 Mar 10;29(8):1083-90, doi: 10.1200/JCO.2010.32.6132. Epub 2011 Jan 24. PMID: 21263087.
206. Gaur P, Xia L, Sceusi EL, F Fan, Samuel S, Zhou Y, Lu J, Vivas-Mejia P, Tozzi F, Rashid A, Lopez-Berestein G, Fleming JB, Abdalla EK, Sood AK, **Curley SA**, Yao JC, Vauthey J-N, Ellis LM. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine

tumors. *Gastroenterology*. 2011 Nov;141(5):1728-37, doi: 10.1053/j.gastro.2011.07.037. Epub 2011 Jul 30. PMID: 21806944.

207. Brouquet A, Vauthey JN, Contreras CM, Walsh GL, Vaporciyan AA, Swisher SG, **Curley SA**, Mehran RJ, Abdalla EK. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. *J Am Coll Surg*. 2011 Jul;213(1):62-69, discussion 69-71, doi: 10.1016/j.jamcollsurg.2011.05.001. PMID: 21700179.
208. Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Cooper A, **Curley SA**, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second line chemotherapy regimen justified? *Cancer*. 2011 Oct 1;117(19):4484-92, doi: 10.1002/cncr.26036. Epub 2011 Mar 28. PMID: 21446046.
209. Raoof M, **Curley SA**. Non-invasive radiofrequency induced targeted hyperthermia for the treatment of hepatocellular carcinoma. *Int J Hepatol*. 2011:676957, doi: 10.4061/2011/676957. Epub 2011 May 29. PMID: 21994866.
210. Andreou A, Brouquet A, Abdalla EK, Aloia TA, **Curley SA**, Vauthey JN. Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. *HPB (oxford)*. 2011 Nov; 13(11):774-782, doi: 10.1111/j.1477-2574.2011.00370. x. Epub 2011 Sep 7. PMID: 21999590.
211. Raoof M, Mackeyev Y, Cheney MA, Wilson LJ, **Curley SA**. Internalization of C60 fullerenes into cancer cells with accumulation in the nucleus via the nuclear pore complex. *Biomaterials*. 2012 Apr;33(10):2952-60 doi: 10.1016/j.biomaterials.2011.12.043. Epub 2012 Jan 14. PMID: 22245558.
212. Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, de Jong MC, Pawlik TM, Geller DA, Tsung A, Marsh JW, Clary BM, **Curley SA**, Gamblin TC. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: A multi-institutional analysis. *J Am Coll Surg*. 2012 May;214(5):767-777, doi: 10.1016/j.jamcollsurg.2011.12.048 Epub 2012 Mar 16. PMID: 22425166.
213. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, **Curley SA**, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. *Surgery*. 2012 May;151(5):7106 doi: 10.1016/j.surg.2011.12.017. Epub 2012 Jan 29. PMID: 22285778.
214. Andreou A, Brouquet A, Bharathy KG, Perrier ND, Abdalla EK, **Curley SA**, Glanemann M, Seehofer D, Neuhaus P, Vauthey JN, Aloia TA. Liver resection for liver metastases from nondigestive endocrine cancer: Extrahepatic disease burden defines outcome. *Surgery* 2012 Jun;151(6):851-859 doi: 10.1016/j.surg.2011.12.025. Epub 2012 Feb 4. PMID: 22306838.
215. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, **Curley SA**. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. *J Surg Res*. 2012 Jul;176(1):147-53, doi: 10.1016/j.jss.2011.09.017. Epub 2011 Oct 5. PMID: 22099584.

216. Zhang T, Liu H, Zhu C, Briggs K, Kang Y, Fleming JA, **Curley SA**. Silencing thioredoxin induces liver cancer cell senescence under hypoxia. *Hepatol Res* 42(7):706-713, 7/2012. e-Pub 3/2012. PMCID: PMC3374013.
217. Tzeng CW, Katz MH, Fleming JB, Pisters PW, Lee JE, Abdalla EK, **Curley SA**, Vauthey JN, Aloia TA. Risk of venous thromboembolism outweighs posthepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients. *HPB (Oxford)*. 2012 Aug;14(8):506-513 doi: 10.1111/j.1477-2574.2012.00479. Epub 2012 May 15. PMID: 22762398.
218. Majumdar A, **Curley SA**, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2012 Sep;9(9):530-8, doi: 10.1038/nrgastro.2012.114. Epub 2012 Jun 19. PMID: 22710573.
219. Glazer ES, Liu P, Abdalla EK, Vauthey JN, **Curley SA**. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. *J Gastrointest Surg*. 2012 Sep;16(9):1666-1671 doi: 10.1007/s11605-012-1935-1. Epub 2012 Jul 10. PMID: 22777053.
220. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmiti G, Brouquet A, Shindoh J, **Curley SA**, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. *Ann Surg*. 2012 Oct;256(4):642-650 doi: 10.1097/SLA.0b013e31826b4dcc.PMID: 22968062.
221. Raoof M, Corr SJ, Kaluarachchi WD, Massey KL, Briggs K, Zhu C, Cheney MA, Wilson LJ, **Curley SA**. Stability of antibody-conjugated gold nanoparticles in the endolysosomal nanoenvironment: Implications for noninvasive radiofrequency-based cancer therapy. *Nanomedicine*. 2012 Oct;8(7):1096-105 doi: 10.1016/j.nano.2012.02.001. Epub 2012 Feb 17. PMID: 22349096.
222. Sahin IH, Shama MA, Tanaka M, Abbruzzese JL, **Curley SA**, Hassan M, Li D. Association of diabetes and perineural invasion in pancreatic cancer. *Cancer Med* 1(3):357-62, 12/2012. e-Pub 10/2012. PMCID: PMC3544459.
223. Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmiti G, **Curley SA**, Charnsangavej C, Aloia TA, Vauthey JN. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. *J Clin Oncol*. 2012 Dec 20;30(36):4566-72 doi: 10.1200/JCO.2012.45.2854. Epub 2012 Nov 13. PMID: 23150701.
224. Corr SJ, Raoof M, Mackeyev, Phounsavath S, Cheney MA, Cisneros BT, Shur M, Gozin M, McNally PJ, Wilson LJ, **Curley SA**. Citrate-capped gold nanoparticle electrophoretic heat production in response to a time-varying radiofrequency electric field. *J Phys Chem Nanomater Interfaces*. 2012 Nov 15;116(45):24380-24389. PMID: 23795228.
225. Raoof M, Zhu C, Kaluarachchi WD, **Curley SA**. Luciferase-based protein denaturation assay for quantification of radiofrequency field-induced targeted hyperthermia: developing an

intracellular thermometer. *Int J Hyperthermia*. 2012 28(3):202-9, doi: 10.3109/02656736.2012.666318. PMID: 22515341.

226. Zimmitti G, Roses RE, Andreou A, Shindoh J, **Curley SA**, Aloia TA, Vauthey JN. Greater complexity of liver surgery is not associated with an increased incidence of liver related complications except for bile leak: An experience with 2628 consecutive resections. *J Gastrointest Surg*. 2013 Jan;17(1):57-64, discussion p.64-5. doi: 10.1007/s11605-012-2000-9. Epub 2012 Sep 7. PMID 22956403.
227. Andreou A, Vauthey JN, Cherqui D, Zimmitti G, Ribero D, Truty MJ, Wei SH, **Curley SA**, Laurent A, Poon RT, Belghiti J, Nagorney DM, Aloia TA, From the International Cooperative Study Group on Hepatocellular Carcinoma. Improved longterm survival after major resection for hepatocellular carcinoma: A multicenter analysis based on a new definition of major hepatectomy. *J Gastrointest Surg*. 2013 Jan;17(1):66-77, discussion p 77. doi: 10.1007/s11605-012-2005-4. Epub 2012 Sep 5. PMID: 22948836.
228. Shindoh J, Truty MJ, Aloia TA, **Curley SA**, Zimmitti G, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. *J Am Coll Surg* 216(2):201-9, 2/2013. e-Pub 12/2012.
229. Tzeng CW, Aloia TA, Vauthey JN, Chang GJ, Ellis LM, Feig BW, **Curley SA**, Skibber JM, Abdalla EK, You YN, Rodriguez-Bigas MA. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: A matched case-control analysis. *Ann Surg Oncol*. 2013 Feb;20(2):482-90 doi: 10.1245/s10434-012-2620-z. Epub 2012 Aug 30. PMID: 22932858.
230. Raoof M, Cisneros BT, Guven A, Phounsavath S, Corr SJ, Wilson LJ, **Curley SA**. Remotely triggered cisplatin release from carbon nanocapsules by radiofrequency fields. *Biomaterials*. 2013 Feb;34(7):1862-9 doi: 10.1016/j.biomaterials. PMID: 23228421.
231. Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, **Curley SA**. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8900 high-risk patients. *HPB (Oxford)*. 2013 Dec;15(12):985-90. doi: 10.1111/hpb.12080. Epub 2013 Apr 22. PMID: 23607636.
232. Corr SJ, Raoof M, Cisneros BT, Kuznetsov O, Massey K, Kaluarachchi WD, Cheney MA, Billups WE, Wilson LJ, **Curley SA**. Cytotoxicity and variant cellular internalization behavior of water-soluble sulfonated nanographene sheets in liver cancer cells. *Nanoscale Res Lett*. 2013 May 2;8(1):208. doi: 10.1186/1556-276X-8208. PMID 23639042.
233. Estrella JS, Othman ML, Taggart MW, Hamilton SR, **Curley SA**, Rashid A, Abraham SC. Intrahepatic Growth of Liver Metastases: Clinicopathologic Features, Prevalence, and Outcome. *Am J Surg Pathol*. 2013 Oct;37(10):1571-9. Doi: 10.1097/PAS.0b013e318293ddf1. PMID: 23797727.
234. Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, **Curley SA**, Abdalla EK, Vauthey JN. Margin Status Remains an Important Determinant of Survival After Surgical Resection of Colorectal Liver Metastases in the Era of Modern Chemotherapy. *Ann Surg*. 2013 Jun;257(6):1079-88, doi: 10.1097/SLA.0b013e318283a4d1. PMID:23426338.

235. Shindoh J, Vauthey JN, Zimmitti G, **Curley SA**, Huang SY, Mahvash A, Gupta S, Wallace MJ, Aloia TA. Analysis of the Efficacy of Portal Vein Embolization for Patients with Extensive Liver Malignancy and Very Low Future Liver Remnant Volume, Including a Comparison with the Associating Liver Partition with Portal Vein Ligation for Staged Hepatectomy Approach. *J Am Coll Surg*. 2013 Jul;217(1):126-33, discussion 133-4. doi: 10.1016/j.jamcollsurg.2013.03.004. Epub 2013 Apr 28. PMID: 23632095.
236. Kaluarachchi WD, Cisneros BT, Corr SJ, Albert ND, **Curley SA**, Kontoyiannis DP. Aspergillus fumigatus hyphal damage caused by noninvasive radiofrequency field hyperthermia. *Antimicrob Agents Chemother*. 2013 Sep;57(9):4444-8. Doi:10.1128/AAC.01017-13. Epub 2013 Jul 8. PMID 23836166.
237. Tzeng CW, **Curley SA**, Vauthey JN, Aloia TA. Distinct predictors of pre- versus postdischarge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patients. *HPB (Oxford)*. 2013 Oct;15(10):773-80. Doi:10.1111/hpb.12130. Epub 2013 Jul 22. PMID: 23869577.
238. Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, **Curley SA**, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α -2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. *Cancer*. 2013 Sep 15;119(18):3334-42. Doi: 10.1002/cncr.28209. Epub 2013 Jul 2. PMID 23821538.
239. Savage DJ, Liu X, **Curley SA**, Ferrari M, Serda RE. Porous silicon advances in drug delivery and immunotherapy. *Curr Opin Pharmacol*. 2013 PMID 23845260.
240. Pascal J, Bearer EL, Wang Z, Koay EJ, **Curley SA**, Cristini V. Mechanistic patientspecific predictive correlation of tumor drug response with microenvironment and perfusion measurements. *Proc Natl Acad Sci U S A*. 2013 Aug 27;110(35):14266-71. doi:10.1073/pnas.1300619110. Epub 2013 Aug 12 PMID: 23940372.
241. Shindoh J, Tzeng CW, Aloia TA, **Curley SA**, Zimmitti G, Wei SH, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. *Ann Surg Oncol*. 2013 Aug;20(8):2493-500 doi: 10.1245/s10434-0122864-7. Epub 2013 Feb 3. PMID: 23377564.
242. Tzeng CW, Cooper AB, Vauthey JN, **Curley SA**, Aloia TA. Predictors of morbidity and mortality after hepatectomy in elderly patients. Analysis of 7,621 NSQIP patients. *HPB (Oxford)*. 2014 May;16(5):459-68. doi:10.1111/hpb.12155. Epub 2013 Aug 26. PMID: 24033514.
243. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, **Curley SA**, Aloia TA, Maru DM. RAS Mutation Stat Hyperthermia inhibits recombination repair of gemcitabine stalled replication forks us Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. *Ann Surg* 258(4):619-27, 10/2013.
244. Shindoh J, Tzeng CW, Aloia TA, **Curley SA**, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Safety and efficacy of portal vein embolization before planned major or extended hepatectomy: An institutional experience of 358 patients. *J Gastrointest Surg*. 2014 Jan;18(1):45-51. doi: 10.1007/s11605-013-2369-0. Epub 2013 Oct 16. PMID: 24129824

245. Raoof M, Aloia TA, Vauthey JN, **Curley SA**. Morbidity and mortality in 1174 patients undergoing hepatic parenchymal transection using a stapler device. *Ann Surg Oncol*. 2014 Mar; 21(3):995-1001. doi:10.1245s10434-013-3331-9. Epub 2013 Nov 9. PMID:24248530
246. Shindoh J, Tzeng CW, Aloia TA, **Curley SA**, Zimmitti G, Wei SH, Huang SY, Gupta S, Wallace MJ, Vauthey JN. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. *Br J Surg*. 2013 Dec;10D (13):1777-83, doi: 10.1002/bjs.9317.
247. Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, ChenTanyolac C, Choi NC, **Curley SA**, et al. A physical sciences network characterization of non-tumorigenic and metastatic cells. *Sci Rep*. 2013; 3:1449. doi: 10.1038/srep01449. PMID: 23618955.
248. Corr SJ, Cisneros BT, Green L, Raoof M, **Curley SA**. Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Noninvasive Hyperthermia Cancer Therapy. *J Vis Exp*. 2013 Aug 28;(78). doi:10.3791/50480. PMID: 24022384.
249. Raoof M, Cisneros BT, Corr SJ, Palalon F, **Curley SA**, Koshkina NV. Tumor selective hyperthermia induced by short-wave capacitively coupled RF electric fields. *PLoS One*. 2013 Jul 4;8(7): e68506. Doi: 10.1371/journal.pone.0068506. Print 2013. PMID:23861912.
250. Das P, Abboud MT, Haque W, Javle M, Kaseb A, **Curley SA**, Vauthey J-N, Aloia TA, Beddar S, Declos ME, Krishnan S, Crane C. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. *Pract Radiat Oncol*. 2013 Oct-Dec;3(4):344-8. doi: 10.1016/j.prro.2012.11.001. Epub 2012 Dec 8. PMID: 24674408.
251. Raoof M, Corr SJ, Zhu C, Cisneros BT, Kaluarachchi WD, Phounsavath S, Wilson LJ, **Curley SA**. Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. *Nanomedicine*. 2014 Aug;10(6):1121-30. doi: 10.1016/j.nano.2014.03.004. PMID: 24650884. Epub 2014 Mar 17.
252. Koshkina NV, Briggs KL, Palalon F, Hamir AN, **Curley SA**. Autophagy and enhanced chemosensitivity in pancreatic cancers induced by non-invasive radiofrequency field treatment. *Cancer*. 2014 Feb 15;120(4):480-91. doi:10.1002/cncr.28453. Epub 2013 Oct 25. PMID: 24496866
253. Kaseb A, Hassan M, Siddiqui A, Lin E, Xiao L, Abdalla EK, Vauthey J-N, **Curley SA**, Aloia TA, Krishnan S, Morris J, Abbruzzese JL. Clinical and prognostic implications of plasma IGF-1 and VEGF in patients with hepatocellular carcinoma. *J Clin Oncol*. 2011 Oct 10;29(29):3892-9. Doi:10.1200/JCO.2011.36.0636. Epub 2011 Sep 12. PMID: 21911725; PMCID: PMC3189091.
254. Abbott DE, Sohn VY, Hanseman D, **Curley SA**. Cost-effectiveness of simultaneous resection and RFA vs. 2-stage hepatectomy for bilobar colorectal liver metastases. *J Surg Oncol*. 2014 May;109(6):516-20. doi:10.1002/jso.23539. Epub 2013 Dec 23. PMID: 24374772.
255. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vathej JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, **Curley S**, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. *Oncology*. 2013;85(4):197-203. doi: 10.1159/000354698. Epub 2013 Sep 19. PMID: 24051705.

256. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, **Curley SA**, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. *Ann Surg*. 2013 Oct;258(4):619-26; discussion 626-7. doi:10.1097 PMID: 24018645.
257. Thomas RM, Aloia TA, Truty MJ, Choi E, **Curley SA**, Vauthey JN, Abdalla EK. Treatment sequencing strategy for hepatic epitheloid hemangio-endothelioma. *HPB (Oxford)*. 2014 Jul;16(7):677-85. doi: 10.1111/hpb.12202. Epub 2013 Dec 6. PMID: 24308564.
258. Shindoh J, Truty M, Aloia TA, **Curley SA**, Zimmitti G, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN. Kinetic Growth Rate after Portal Vein Embolization Predicts Posthepatectomy Outcomes: Toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. *J Am Coll Surg*. 2013 Feb; 216(2):201-209. doi: 10.1016/j.jamcollsurg.2012.10.018. Epub 2012 Dec 7. PMID: 23219349.
259. Raoof M, Zhu C, Cisneros BT, Liu H, S, Corr SJ, Wilson LJ, **Curley SA**. Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks. *J Natl Cancer Inst* 2014 Aug 15; 106(8). doi:10.1093/jnci/dju183. PMID: 25128695; PMC4155430.
260. Zimmitti G, Roses RR, Andreou A, Shindoh J, **Curley SA**, Aloia TA, Vauthey JN. Greater complexity of liver surgery is not associated with an increased incidence of liver-related complications except for bile leak: an experience with 2,628 consecutive resections. *JGastrointest Surg*. 2013 January; 17(1): 10.1007/s11605-012-2000-9. Published online 2012 September 7. doi: 10.1007/s11605-012-2000-9. PMCID: PMC3855461.
261. **Curley SA**, Palalon F, Koshkina V. Non-invasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells. *Cancer*. 2014 Nov 1;120(21):3418-25. doi: 10.1002/cncr.28895. Epub 2014 Jul 1. PMID: 24986120
262. Abbott D, Hanseman D, Sohn V, **Curley SA**. Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases. *J Surg Oncol*. 2014 May; 109(6):516-20. doi: 10.1002/jso.23539. Epub 2013 Dec 23. PMID: 24374772 [PubMed indexed for MEDLINE]
263. **Curley SA**, Palalon F, Sanders KE, Briggs K, Koshkina NV. The effects of noninvasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells. *Int J Environ Res Public Health*. 2014 Sep 3;11(9)9142-53. doi:10.339D. PMID:25192147 PMCID: PMC4199010.
264. Bogdanov AA, Gupta S, Koshkina N, Zhang S, **Curley SA**, Han G. Gold nanoparticles stabilized with MPEG-Grafted Poly(L-lysine): in Vitro and in Vivo Evaluation of a potential theranostic agent. *Bioconjug Chem*. 2015 Jan 21, 26(1):39-50. Doi: 10.1021/bc5005087. Epub Dec 2014 11. PMID: 25496453
265. Soliz JM, Gebhardt R, Feng L, Dong W, Reich M, **Curley SA**. Comparing epidural analgesia and ON-Q infiltrating catheters for pain management after hepatic resection. *Open J Anesthesiol*. 2013 Jan 1;3(1):3-7. PMID: 25580374
266. Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic AK, Nogueras-Gonzalez GM, Janku F, Shroff RT, Aloia TA, Vauthey JN, **Curley S**, Mills G, Roa I. Molecular characterization of gallbladder

cancer using somatic mutation profiling. *Hum Pathol.* 2014 Apr;45(4):701-8. doi: 10.1016/j.humpath.2013.11.001. Epub 2013 Nov 12. PMID: 24508317.

267. Neve Polimeno M, Ierano C, D'Alterio C, Simona Losito N, Napolitano M, Portella L, Scognamiglio G, Tatangelo F, Maria Trotta A, **Curley S**, Costantini S, Liuzzi R, Izzo F, Scala S. CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not. *Cell Mol Immuno.* 2015 Jul;12(4):474-82. doi:10.1038/cmi.2014.102. Epub 2014 Nov 3. PMID: 25363530.
268. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, **Curley SA**, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. *J Natl Cancer Inst.* 2014 May 9;106(5) pii: dju088.doi:10.1093 PMID: 24815863.
269. Mackeyev Y, Raoof M, Cisneros B, Koshkina N, Berger CS, Wilson LJ, **Curley SA**. Toward paclitaxel-[60] fullerene immunoconjugates as a targeted prodrug against cancer. *Nanosystems: Physics, Chemistry, Mathematics*, 2014.5(1):67-75. PACS 81.20. Ka; 81.05.ub; 87.19xj; 87.85Qr, 87.85Rs
270. Ware MJ, Tinger S, Colbert KL, Corr SJ, Rees P, Koshkina N, **Curley SA**, Summers HD, Godin B. Radiofrequency treatment alters cancer cell phenotype. *Sci Rep.* 2015 Jul 13; 5:12083. Doi:10.1038/srep 12083. PMIC: 26165830 PMCID: PMC4499808.
271. Corr SJ, Shamsudeen S, Ho JC, Ware MJ, Keshishian V, Yokoi K, Savage D, Meraz I, Kaluarachchi W, Cisneros B, Raoof M, Nyugen DT, Zhang Y, Wilson LJ, Summers H, Rees P, **Curley SA**, Serda R. A New Imaging Platform for Visualizing Biological Effects of Non-Invasive Radiofrequency Electric Field Cancer Hyperthermia. *PLOS ONE.* 2015 Aug 26;10(8): e 0136382. doi 10.1371/journal.pone.0136382. eCollection 2015. PMID: 26308617; PMCID: PMC4550384.
272. Corr SJ, Raoof M, Cisneros BT, Orbaek AW, Cheney MA, Law JJ, Lara NC, Barron AR, Wilson LJ, **Curley SA**. Radiofrequency Electric-Field Heating Behaviors of Highly Enriched Semiconducting and Metallic Single-Walled Carbon Nanotubes. *Nano Res.* 2015. doi.10.1007/s12274-015-0791-1
273. Gehlot P, Gupta S, Shareef MM, **Curley SA**. Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells. *J Transl Med.* 2016 Feb 12:14:49. doi:10.1186/s12967-016-0785-0. PMID: 26873175
274. Ware MJ, Colbert K, Keshishian V, Summer HD, **Curley SA**, Godin B. Generation of homogenous 3D pancreatic cancer cell spheroids using an improved hanging drop technique. *Tissue Eng Part C Methods.* 2016 Apr;22(4):312-21. doi:10.1089/ten. TEC.2015.0280. Epub 2016 Mar 9. PMID: 26830354.
275. Chen H, Wei Z, Sun J, Bhattacharya A, Savage D, Serda R, Mackeyev Y, **Curley SA**, Bu P, Wang L, Chen S, Cohen-Gould L, Huang E, Shen X, Lipkin S, Copeland N, Jenkins N. A recellularized human colon model identifies cancer driver genes. *Nat biotechnol.* 2016 Aug;34(8):845-51. doi:10.1038/nbt.3586. Epub 2016 Jul 11. PMCID: 27398792 PMC4980997.

276. Lapin N, Krzykawska-Serda M, Ware MJ, **Curley SA** and Corr SJ. Intravital microscopy for evaluating tumor perfusion of nanoparticles exposed to non-invasive radiofrequency electric fields. *Cancer Nanotechnol.* 2016; 7:5. Epub 2016 Jun 30. PMID: 2749662.
277. Ho J, **Curley SA**. Diagnosis and management of intrahepatic and extrahepatic cholangiocarcinoma. *Cancer Treat Res* 2016: 168:121-163.
278. Wang Z, Kerketta R, Chuang Y, Dogra P, Butner JD, Brocato T, Day A, Xu R, Shen H, Simbawa E, Al-Fhaid AS, Mahmoud SR, **Curley SA**, Ferrari M, Koay E and Cristini V. Theory and Experimental Validation of a Spatio-Temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill. *PLoS Comput Biol.* 2016 Jun 10; 12(6): e1004969. doi: 10.1371/journal.pcbi.1004969. eCollection 2016 Jun. PMID: 27286441.
279. Lakoma, A, **Curley SA**. Clinical manifestations of late isolated metachronous brain metastases after colorectal cancer hepatic metastectomy. *Clin Onc*; 06 Sep 2016.1:1071
280. Lara NC, Haider AA, Ho JC, Wilson LJ, Barron AR, **Curley SA**, and Corr SJ. Water structuring molecules and nanomaterials enhance radiofrequency heating in biologically relevant solutions. *Chem Commun (Camb)* 2016 Oct 18;52(85):1263012633. doi:10.1039/c6cc06573b PMID: 27722511.
281. Ware MJ, Keshishian V, Law JJ, Ho JC, Favela CA, Rees P, Smith B, Mohammad S, Hwang RF, Rajapakshe K, Coarfa C, Huang S, Edwards DP, Corr SJ, Godin B, and **Curley SA**. Generation of an *in vitro* 3D PDAC stroma rich spheroid model. *Biomaterials.* 2016 Nov; 108:129-42. Epub 2016 Sep 2. doi:10; 1016/j.biomaterials.2016.08.041. PMID: 27627810.
282. Bimonte S, Leongito M, Piccirillo M, Tamma ML, Vallifuoco M, Bracco A, Mancini A, Di Napoli D, Castaldo S, Cozzolino S, Iacobellis F, Grassi R, Granata V, Lastoria S, **Curley SA**, Izzo F. Induction of VX2 para-renal carcinoma in rabbits: generation of animal model for loco-regional treatments of solid tumors. *Infect Agent Cancer.* 2016 Dec 1; 11:62. PMID: 27980609.
283. Lara NC, Haider AA, Wilson LJ, **Curley SA**, and Corr SJ. Unique heating curves generated by radiofrequency electric-field interactions with semi-aqueous solutions. *Appl Phys Lett.* 2017 Jan 2;110(1): 013701.doi:10.1063/1.4973218. PMID: 28104923.
284. Ware MJ, Curtis LT, Wu M, Ho JC, Corr SJ, **Curley SA**, Godin B, and Frieboes HB. Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach. *Sci Rep.* 2017 Jun 13;7(1):3437. PMID: 28611425 DOI: 10.1038/s41598-017-03040-0.
285. Rosengart, TK, Mason MC, LeMaire SA, Brandt ML, Coselli JS, **Curley SA**, Mattox KL, Mills JL, Sugarbaker DJ, Berger DA. The seven attributes of the academic surgeon: critical aspects of the archetype and contributions to the surgical community. *Am J Surg.* 2017 Feb 20. DOI: 10.1016/j.amjsurg.2017.02.003. PMID: 28284432.
286. Ware MJ, Krzykawska-Serda M, Chak-Shing Ho J, Newton J, Suki S, Law J, Nguyen L, Keshishian V, Serda M, Taylor K, **Curley SA**, Corr SJ. Optimizing non-invasive radiofrequency hyperthermia treatment for improving drug delivery in 4T1 mouse breast cancer model. *Sci Rep.* 2017 Mar 137:43961. PMID: 28287120 PMCID: 5347121. Doi:10.1038/srep43961.

287. Ho JC, Nguyen L, Law JJ, Ware, MJ, Keshishian V, Lara NC, **Curley SA** and Corr SJ. Non-invasive Radiofrequency Field Treatment to Produce Hepatic Hyperthermia: Efficacy and Safety in Swine. *Journal of Translational Engineering in Health and Medicine*. IEEE J Transl Eng Health Med. 2017 Apr 3;5:1500109. Doi:10.1109/JTEHM.2017.2672965. eCollection 2017. PMID: 28507824
288. Lapin NA, Krzykawska-Serda M, Dilliard S, Mackeyev Y, Serda M, Wilson LJ, **Curley SA**, and Corr SJ. The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60] fullerene derivative in a murine orthotopic model of breast adenocarcinoma. *J Control Release*. 2017 May 17. Pii: S0168-3659(17)30595-3. Doi: 10.1016/j.jconrel.2017.05.022 [Epub ahead of print] PMID: 28527736.
289. Ware MJ, Nguyen LP, Law JJ, Krzykawska-Serda M, Taylor KM, Cao HST, Anderson AO, Pulikkathara M, Newton JM, Ho JC, Hwang R, Rajapakshe K, Coarfa C, Huang S, Edwards D, **Curley SA**, Corr SJ. A new mild hyperthermia device to treat vascular involvement in cancer surgery. *Sci Rep*. 2017 Sep 12;7(1):11299. doi:10.1038/s41598-017-10508-6. PMID:28900126.
290. Tran Cao HS, Zhang Q, Sada YH, Chai C, **Curley SA**, and Massarweh NN. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. *Cancer*. 2017 Aug 25. Doi:10.1002/cncr.30968 PMID: 28841223.
291. Lapin NA, Vergara LA, Mackeyev Y, Newton JM, Dilliard SA, Corr SJ, Wilson LJ, **Curley SA**, and Serda RE. Biotransport kinetics and intratumoral biodistribution of malonodiserinolamide-derivatized [60] fullerene in a murine model of breast adenocarcinoma. *International Journal of Nanomedicine*. 2017 Nov 15(12):8289-8307. Doi.org/10.2147/ijn.138641. eCollection 2017. PMID: 29180866.
292. Currell F, **Curley S**, Krpetic Z, Bellringer M. From basics to clinic: Cancer Nanotechnology. *Cancer Nanotechnol*. 2017;8(1):8. Doi: 10.1186/s12645-017-00331. Epub 2017 Nov 10. No abstract available. PMID: 29170684.
293. Newton JM, Flores-Arredondo JH, Suki S, Ware MJ, Krzykawska-Serda M, Agha M, Law JJ, Sikora AG, **Curley SA**, Corr SJ. Non-invasive radiofrequency field treatment of 4T1 breast tumors induces T-cell dependent inflammatory response. *Sci Rep*. 2018 Feb 22;8(1):3474. Doi:10.1038/s41598-018-21719-w. PMID: 29472563.
294. Corr S, Newton J, Nguyen L, Agha M, Krzykawska-Serda M, Ware M, **Curley SA**, Ho J, Law J. Chemotherapy and radiofrequency-induced mild hyperthermia combined treatment of orthotopic pancreatic ductal adenocarcinoma xenografts. *Transl Oncol*. 2018 Apr2;11(3):664-671. Doi: 10.1016/j.tranon.2018.02.023 [Epub ahead of print] PMID: 29621664.
295. Cotton RT, Tran Cao HS, Rana AA, Sada YH, Axelrod DA, Goss JA, Wilson MA, **Curley SA**, and Massarweh NN. Impact of the treating hospital on care outcomes for hepatocellular carcinoma. *Hepatology*. 2018 Aug. 2. Doi: 10.1002/hep.30128. {Epub ahead of print} PMID: 30070392.
296. Serda M, Ware MJ, Newton JM, Sachdeva S, Krzykawska-Serda M, Nguyen L, Law J, Anderson AO, Curley SA, Wilson LJ, Corr SJ. Development of photoactive sweet C₆₀ for pancreatic cancer stellate therapy. *Nanomedicine* 2018: 13(23):2981-2993.

297. Serda M, Ware MJ, Newton JM, Sachdeva S, Krzykawska-Serda M, Law J, Anderson AO, **Curley SA**, Wilson NJ, Corr SJ. Development of photoactive sweet-C60 fullerenes for pancreatic cancer stellate therapy. *Nanomedicine* 2018; 13(23):2981-2993.
298. Krzykawska-Serda M, Ho JC, Ware MJ, Law JJ, Newton JM, Nguyen L, Agha MS, **Curley SA**, Corr S. Ultrasound Doppler as an imaging modality for selection of murine 4T1 breast tumors for combination radiofrequency hyperthermia and chemotherapy. *Translational Oncology*. 2018 11(4):864-872.
299. Krzykawska-Serda M, Agha MS, Ho JC, Ware MJ, Law J, Newton JM, Nguyen L, **Curley SA**, Corr S. Chemotherapy- and radiofrequency-induced mild hyperthermia combined treatment of orthotopic pancreatic ductal adenocarcinoma xenografts. *Translational Oncology*. 2018; 11(3):664-671.
300. Ho J, Ware MJ, Law J, Nagaraj A, Jain S, Rios J, Calderon R, Toombs B, Anderson AO, Bray C, **Curley SA**, Corr SJ. Improved, shorter latency carcinogen-induced hepatocellular carcinoma in pigs. *Oncology*, Sep 28, 2018:1-10.
301. **Curley SA**, Dogra P, Butner JT, Wang Z, Cristini V. A novel mechanistic mathematical model of the heat equation and energy balance for absorption of non-invasive radiofrequency (RF) energy in biologic tissues. *Open Access Government*. 2018 May. ISSN:2516-3817, 78-79.
302. Granata V, Fusco R, Sansone M, Grassi R, Maio F, Palaia R, Tatangelo F, Botti G, Grimm R, **Curley SA**, Izzo F, Petrillo A. Dynamic contrast-enhanced magnetic resonance imaging, diffusion kurtosis imaging, and intravoxel incoherent motion diffusion-weighted imaging: MRI functional parameters in the assessment of pancreatic cancer. *Magnetom Flash*. 2018; 70(1):51-59.
303. Ware MJ, Newton J, Krzykawska-Serda M, Ho J, Law J, Anderson AO, Byrd HF, Herbst M, McDowell MW, Marti AA, Agha M, Jain S, Mohammed S, Rajapakshe K, Huang S, Edwards DP, Godin B, **Curley SA**, Corr SJ. Incremental gemcitabine dose regimen for the isolation of drug resistant pancreatic ductal adenocarcinoma subpopulations. *Stem Cells Int*. 2018. Article 7411141.
304. Vo E, **Curley SA**, Chai CY, Massarweh NN, Tran Cao HS. National failure or surgical staging for T1b gallbladder cancer. *Ann Surg Oncol*. 2018 Nov 29. doi:10.1245/s10434-018-7064-7. Epub PMID:30499077.
305. Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carradiello G, Azoulay D, Petrillo A, **Curley SA**. Radiofrequency ablation and microwave ablation in liver tumors: an update. *The Oncologist*. 2019 24:1-16. PMID:31217342.
306. Chen HJ, Wei Z, Sun J, Bhattacharya A, Savage DJ, Serda R, Mackeyev Y, **Curley SA**, Bu P, Wang L, Chen S, Cohen-Gould L, Huang E, Shen X, Lipkin SM, Copeland NG, Jenkins NA, Shuler ML. A recellularized human colon model identifies cancer driver genes. *Nat Biotechnol*. 2019; 37(7):820. PMID:31160724.
307. Budillon A, Curley SA, Fusco R, Mancini R. Identification and targeting of stem cell-activated pathways in cancer therapy. *Stem Cells Int*. Jun 4, 2019:8549020. Doi:10.1155/2019/8549020. PMID:3121388.

308. Ogle M, Smith-McWilliams A, Ware MJ, **Curley SA**, Corr SJ, Marti AA. Sensing temperature *in vitro* in cells using a BODIPY molecular probe. J Physical Chem. Aug 29, 2019: 123(34):7282-7289. PMID:3149279.
309. Gerdtsen AS, Thiele JA, Shishido SN, Zheng S, Schaffer R, Bethel K, **Curley SA**, Lenz HJ, Hanna DL, Nieva J, Kolatka AR, Ruiz C, Rodriguez-Lee M, Oakley III GJ, Lee JSH, Hicks J, Kuhn P. Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. Oncotarget. Dec 17, 2019: 10(66)7016-7030. PMID:6925029.
310. Shin CS, Lee R, Kim J, Cabrera F, Veettil RA, Zaheera M, Adumbumkulath A, Mhatre K, Ajayan PM, **Curley SA**, Scott BG, Acharaya G. 3D-bioprinted inflammation modulating polymer scaffold for soft tissue repair. Advanced Materials. Epub Dec 16, 2020. Doi:10.1002/adma.202003778. PMID:33325594.
311. Serda M, Malarz K, Mrozek-Wilczkiewicz A, Wojtyniak M, Musiol R, **Curley SA**. Glycofullerenes as non-receptor tyrosine kinase inhibitors: towards better nanotherapeutics for pancreatic cancer treatment. Sci Rep 2020: 14;10(1)260. Doi:10.1038/s41598-019-57155-7. PMID:31937861.
312. Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh JW, Hasegawa N, Mittendorf EA, **Curley SA**, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Early predictor of clinical response to checkpoint inhibitors in human solid tumors through mathematical modeling. Elife 2021; 9:10: e70130. Doi:10.7554/eLife.70130. PMID:34749885.
313. Ward WH, Hui J, Davis CH, Li T, Goel N, Handorf E, Ross EA, **Curley SA**, Karachristos A, Esnaola N. Perioperative outcomes following combined versus isolated colorectal and liver resections: insights from a contemporary, national, propensity score-based analysis. Ann Surg Open Mar 2021: 11;2(1): e050. Doi:10.1097/AS90000000000000050. PMID:36714392.
314. Blutt SE, Crawford S, Bomidi C, Zeng XL, Broughman JR, Robertson M, Coarfa C, Tessier MEM, Savidge T, Hollinger FB, **Curley SA**, Donowitz M, Estes MK. Use of human tissue stem cell-derived organoid cultures to model enterohepatic circulation. Am J Physiol GI 2021: ePub Jul 21, 2021; doi:10.1152/ajpgi.00177.2021.
315. Izzo F, Mason M, Silberfein E, Massarweh N, Hsu C, Tran Cao H, Palaia R, Piccirillo M, Granata V, **Curley SA**. Long-term survival and curative-intent treatment in hepatitis B and C virus-associated hepatocellular cancer patients diagnosed during screening. Biology. 2022 1;11(11):1597-1605.
316. Liver Group.org Collaborative. Outcomes of elective liver surgery worldwide: a global, prospective, multicenter, cross-sectional study. Int J Surg. 2023 1;109(12):3954-3966.

2. Other Full Invited Papers

1. **Curley SA**, Cameron JL. A diagnostic and therapeutic challenge. Cancer Bull 44(4), 1992.

2. Talamonti MS, **Curley SA**, Gallick GE, Teeter L, Kuo MT. Development and progression of human colon cancer. *Cancer Bull* 44(4):309-315, 1992.
3. Skibber JM, **Curley SA**, Lotan R. Colon tumor markers for prognosis and therapy. *Cancer Bull* 46:331-335, 1994.
4. **Curley SA**, Newman RA, Dougherty TB, Fuhrman GM, Stone DL, Mikolajek JA, Guercio S, Guercio A, Carrasco CH, Kuo MT. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: A phase I study. *Ann Surg Oncol* 1:389-399, 1994.
5. Radinsky R, **Curley SA**, Roh MS. Recent advances in the biology and therapy of colon carcinoma liver metastases. *Cancer Bull* 46:352-358, 1994.
6. **Curley SA**. Preclinical and clinical trials of isolated liver perfusion for primary liver cancers. *Cancer Reports: Bulletin of the National Cancer Institute of Italy* 18:23-34, 1996.
7. Izzo F, Newman RA, **Curley SA**. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma. *J Chemotherapy* 10:507-508, 1997.
8. **Curley SA**. Surgical treatments for hepatocellular cancer. *Gastroenterology International* 10:507-508, 1997.
9. **Curley SA**, Vecchio R. New trends in the surgical treatment of colorectal cancer liver metastases. *Tumori* 84:281-288, 5/1998.
10. Pearlstone DB, **Curley SA**, Feig BW. The management of gallbladder cancer: before, during, and after laparoscopic cholecystectomy. *Semin Laparosc Surg* 5:121-128, 6/1998.
11. Pollock R, **Curley SA**. Training for careers in academic surgical oncology: The future is bright. *Ann Surg Oncol* 6(6):517-518, 1999.
12. Barnett CC, Jr, **Curley SA**. Ablative techniques for hepatocellular carcinoma. *Semin Oncol* 28:487-496, 10/2001.
13. **Curley SA**, Izzo F. Radiofrequency ablation of primary and metastatic liver tumors. *Surg Technol Int*:99-106, 2001.
14. **Curley SA**, Izzo F. Radiofrequency ablation of hepatocellular carcinoma. *Minerva Chir* 57:165-1676, 4/2002.

15. **Curley SA**, Izzo F. Radiofrequency ablation of primary and metastatic hepatic malignancies. *Int J Clin Oncol* 7:72-81, 4/2002.
16. **Curley SA**. Radiofrequency ablation of malignant liver tumors. *Ann Surg Oncol* 10:338347, 5/2003.
17. **Curley SA**, Bilchik AJ, Fraker DL, McMasters KM. Radiofrequency ablation of hepatic malignancies. *Contemporary Surgery* 59(4):162-173, 2003.
18. Tanabe KK, **Curley SA**, Dodd GD, Siperstein AE, Goldberg SN. Radiofrequency ablation: the experts weigh in. *Cancer* 100:641-650, 2/2004.
19. **Curley SA**, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer metastasis. *Cancer Metastasis Rev* 23:165-182, 2004.
20. **Curley SA**. One surgeon's unabashedly biased view on liver resection. *J Clin Oncol* 23:8286-8288, 2005.
21. **Curley SA**. Outcomes after surgical treatment of colorectal cancer liver metastases. *Semin Oncol* 32:109-111, 2005.
22. Benson AB, 3rd, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BM, **Curley SA**, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA, Jr., Posey JA, Sigurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ. Hepatobiliary cancers. Clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 4:728-750, 2006.
23. Beaty KA, **Curley SA**. Emerging trends of metastatic colorectal cancer to the liver: Metastasectomy for combined hepatic and extrahepatic colorectal cancer metastases. In: *Current Colorectal Cancer Reports*. Current Science, Inc 3(2):89-93, 2007
24. **Curley SA**. Surgical treatment of colorectal cancer liver metastases. *Gastrointestinal Malignancies: JWC Covenant, Inc.* 1 (1): 2-8, 2007.
25. **Curley SA**. Radiofrequency ablation vs. resection for resectable colorectal liver metastases: time for a randomized trial. *Ann Surg Onc* 15(1):11-13, 2008.
26. Cherukuri P, **Curley SA**. Use of nanoparticles for targeted, non-invasive thermal destruction of malignant cells. *Methods Mol Bio* 624:359-373, 2010.

27. Cusack JC, Clark JW, **Curley SA**, Sahani DV, Zuckerberg LR. Case 3-2011: A 58-year-old woman with a mass in the liver. *N Engl J Med*. 2011 Jan 27;364(4):362-70, doi 10.1056/NEJMcpc1000965. PMID: 21267829.
28. Glazer ES, **Curley SA**. Non-invasive RF ablation of malignancies mediated by quantum dots, gold nanoparticles, and carbon nanotubes. *Ther Delivery* 2(10):1325-1330, 2011.
29. Cooper AB, **Curley SA**. Surgical treatment of colorectal liver metastases. *Chin Clin Oncol* 2(2):15, 2013.
30. Curley SA, Currell F, Krishnan S, Krpetic Z. Cancer research, treatment, and COVID-19. *Cancer Nanotechnol* 2020; 11(1):7. Epub 2020 Aug 6. PMID: 32834865.

3. Books for the public regarding cancer

1. Curley Steven. In My Hands: Compelling Stories from a Surgeon and His Patients Fighting Cancer. Center Street Publishers, Hachette Book Group. Nashville, 2018.

4. Abstracts

1. Hassabo JM, Kaseb AO, Shama MA, Vauthey J, Lozano RD, **Curley SA**. Association between prior history of cholecystectomy and hepatocellular carcinoma (HCC) development: A case-control study in the United States. *ASCO Annual Meeting* (#e14643), 2010.
2. Shama MA, Tanaka M, Curley SA, Abbruzzese JL, Li D. Association of diabetes with perineural invasion and overall survival in surgically resected patients with pancreatic cancer. *J Clin Oncol* 28(Suppl 15): abstr 4117, 2010 PMID: 23342285.
3. Glazer ES, Stone EM, Kaluarachchi WD, Chantranupong L, Massey KL, Georgiou G, **Curley SA**. Bioengineered human L-Arginase is cytotoxic to hepatocellular and pancreatic Carcinoma cells through induction of proapoptotic pathways. *J Surg Res* 158(2):339-339, 2010.
4. Glazer ES, Stone EM, Kaluarachchi WD, Massey KL, Chantranupong L, Georgiou G, **Curley SA**. Effect of bioengineered arginase on apoptosis and proliferation in hepatocellular and pancreatic carcinoma cell lines. *ASCO Gastrointestinal Cancers Symposium* (#160), 2010.
5. Glazer ES, Ellis V, Abdalla EK, Vauthey JN, **Curley SA**. Neoadjuvant and adjuvant therapy does not improve survival in resected biliary cancers. *Ann Surg Onc* 17: S89, 2010.

6. Glazer ES, Massey KL, **Curley SA**. Noninvasive radiofrequency field therapy induces cell death in human pancreatic carcinoma cells targeted with gold nanoparticles. *J Surg Res* 158(2):195, 2010.
7. Shama MA, Kaseb AO, Vauthey J, Hassan M, Phan AT, Siddiqui AM, Nooka AK, Abbruzzese JL, Abdalla EK, **Curley SA**. Retrospective analyses of 52 patients with fibromellar hepatocellular carcinoma: Treatment outcome and prognostic indicators. *ASCO Gastrointestinal Cancers Symposium (#203)*, 2010.
8. Glazer ES, Tseng JF, Willborn KA, Liu P, Al-Reafaie W, Abdalla EK, Vauthey JN, **Curley SA**. Surgical treatment of neuroendocrine metastases yields an almost 10-year median survival. *HPB* 12(S1):29, 2010.
9. De Jong M, Geller DA, Marsh JW, Pawlik TM, Clary BM, **Curley SA**, Gamblin TC. Hepatic metastesectomy for noncolorectal and nonendocrine cancer. *Ann Surg Oncol* 18(Suppl 1): S75, 2011.
10. Glazer ES, **Curley S**, Albino V, Palaia R, Piccirilio M, Giacomo R, Izzo F. Long-term survival after radiofrequency ablation for cirrhotics with unresectable hepatocellular carcinoma. *Ann Surg Oncol* 18(Suppl 1): S89, 2011.
11. Abbott DE, Brouquet A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, **Curley SA**, Abdalla EK, Hunt K, Vauthey J. Resection of liver metastases from breast cancer: Effect of timing of surgery and estrogen receptor status on outcome. *J Clin Oncol* 29(Suppl 4): abstr 288, 2011.
12. Abbott D, Brouquet A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, **Curley SA**, Abdalla EK, Hunt KK, Vauthey J. Resection of liver metastases from breast cancer: Timing of surgery and estrogen receptor status define outcome. *Ann Surg Oncol* 18(Suppl 1): S80, 2011.
13. Raoof M, **Curley S**, Pollock R. True myomatous tumors of the gastrointestinal tract. *Ann Surg Oncol* 18(Suppl 1): S124, 2011.
14. Green LJ, Koshkina N, **Curley SA**. Histone deacetylase inhibitor, vorinostat, as an enhancer of gemcitabine therapy for resistant pancreatic tumors. *Ann Surg Oncol*: P367. ePub 2012.
15. Green L, Koshkina N, **Curley SA**. Histone deacetylase inhibitor, vorinostat, decreases transcription of survivin and is an enhancer of gemcitabine therapy for resistant pancreatic tumors. *AACR Meeting*, Chicago, 2012.
16. Tzeng C-W D, Chang GJ, **Curley SA**, Vauthey J-N, Ellis LM, Skibber JM, Feig BW, Abdalla EK, Aloia TA, You N, Rodriguez-Bigas MA. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: A matched case-control analysis. *J Clin Oncol* 30(Suppl 4): abstract+- 629, 2012.

17. Raoof M, **Curley SA**. Non-invasive radiofrequency field-induced hyperthermia sensitizes murine hepatocellular carcinoma xenografts after targeted delivery of gemcitabine. *Ann Surg Oncol*: S17. e-Pub 2012.
18. Koshkina NV, Briggs K, Palalon F, **Curley SA**. Non-invasive radiofrequency increases the anticancer effect of gemcitabine in treating pancreatic cancer via autophagy. *AACR Annual Meeting*, Chicago, 2012.
19. Vauthey J-N, Zimmitti G, Shindoh J, Chen SS, Kopetz S, Andreou A, **Curley SA**. Ras mutational status predicts patterns of recurrence and survival in patients undergoing hepatectomy for colorectal liver metastases. *American Surgical Association*, 2012.
20. Tzeng CD, Katz MH, Fleming JB, Pisters PW, Lee JE, Abdalla EK, **Curley SA**, Vauthey JN, Aloia TA. Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: Analysis of 5651 NSQIP patients. *HPB* 14:72, 2012.
21. Corr S, Gizzatov A, Cisneros B, Wilson L, **Curley SA**. Cytotoxicity and biocompatibility of highly water-soluble graphene nanoribbons derivitized with p-carboxyphenyldiazonium salt. *223rd ECS Meeting*, Toronto, 2013.
22. **Curley SA**. Targeted nanoparticles for non-invasive hyperthermia in malignant disease. *American Chemical Society National Meeting and Exposition* 2013, 2013.
23. Kaseb AO, Morris J, Xiao L, Rehem R, El-Shikh W, Hassan M, Vierling J, Jalal P, Wallace MJ, Vauthey J-N, Aloia TA, **Curley SA**, Overman MJ, Krishnan S, Abbruzzese JL. Development and validation of a new molecular child-pugh score to stratify hepatocellular carcinoma patients in clinical trials. *ASCO Meeting*.
24. Shroff RT, Churi C, Rashid A, Mishra L, Zuo M, Kaseb AO, Janku F, Aloia TA, Vauthey J-N, **Curley SA**, Javle MM. Next generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
25. Haque W, Das P, Javle M, Kaseb A, **Curley SA**, Vauthey J-N, Abdalla EK, Delclos ME, Krishnan S, Crane CH. Radiation therapy for intrahepatic cholangiocarcinoma. *International Society of Gastrointestinal Oncology*.
26. Gehlot P, Mackeyev Y, **Curley S**. Fullerenes combined with radiofrequency exposure cause cell death in HCC through apoptosis. *BMES 2014 Annual Meeting*. San Antonio, TX, October 2014.
27. MJ Ware, V Keshishian, R Serda, S Corr, B Godin, **S Curley**. Tunneling nanotubes as a conduit for drug resistance transfer. *BMES 2015 Annual Meeting*. October 2015, Tampa FL.

28. Tran Cao HS, Zhang Q, Sada YH, Chai C. **Curley SA**, and Massarweh NN. The Role of surgery and adjuvant therapy in node-positive biliary tract cancer. SSO 2017: Annual Cancer Symposium. March 2017, Seattle WA.
29. Curley SA. The intersection of surgery and bioengineering: innovative solutions for clinical problems in pancreatic and other cancers. AHPBA 2018, March 2018, Miami Beach, FL.

4. Books

a. Complete Books Written

Curley SA. In My Hands; Compelling Stories from a Surgeon and His Patients Fighting Cancer. Center Street Publishers, Hachette Book Group. Nashville, 2018

b. Books Edited (include names of other editors, if applicable)

1. **Curley SA**, Editor. Liver Cancer. Springer Verlag Publishers: New York, 1998.
2. Ellis LM, **Curley SA**, Tanabe KK, Editors. Current Indications, Techniques and Outcomes. In: Radiofrequency of Cancer. Springer-Verlag Publishers: New York, 2003.
3. Pollock RE, **Curley SA**, Ross MI, Perrier ND (Editors). Advanced Therapy in Surgical Oncology. BC Decker Inc.: Hamilton, 2008.

c. Book Chapters Written

1. **Curley SA**, Balch CM. Hepatic arterial infusion chemotherapy. In: Current Surgical Therapy, 5th Edition. Mosby-Yearbook Publishers: St. Louis, 289-296, 1995.
2. Rich TA, **Curley SA**, Evans DB, Leach SD, Lowy AM, Skibber JM. Intraoperative radiotherapy experience at M. D. Anderson Cancer Center. In: Progress in RadioOncology, V Edition. Monduzzi Editore: Italy, 579-583, 1995.
3. **Curley SA**, Levin B, Rich TA. Liver and bile ducts. In: Clinical Oncology. Churchill Livingstone: New York, 1305-1372, 1995.
4. **Curley S.** Update on regional treatments for hepatobiliary malignancies. In: Proceedings of the Society of Regional Chemotherapy. Volume 22. Tokyo Medical Publishers: Tokyo, 1437-1451, 1995.
5. Lowy AM, **Curley SA**. Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors. In: Primary Liver Tumors. Surg Oncol Clinics, 429-442, 1996.

6. **Curley S.** Hepatocellular cancer. In: Current Hepatology. Volume 16. MosbyYearbook Publishers: St. Louis, 429-442, 1996.
7. **Curley SA.** Biliary tract cancer. In: Surgical Oncology. Kluwer Academic Press: Norwell, 273-308, 1997.
8. Izzo F, **Curley SA.** Diagnosis and management of hepatobiliary cancer. In: Edizione Hermes, 1-124, 1997.
9. Izzo F, Fiore F, de Werra C, **Curley SA.** Alternative treatment approaches in patients with early stage or unresectable hepatocellular cancer confined to the liver. In: Liver Cancer. Springer Verlag Publishers: New York, 79-94, 1998.
10. **Curley SA.** Diagnosis and treatment of primary gallbladder cancer. In: Liver Cancer. Springer Verlag Publishers: New York, 117-135, 1998.
11. Ellis LM, Chase J, Patt Y, **Curley SA.** Hepatic arterial chemotherapy for colorectal cancer liver metastasis. In: Liver Cancer. Springer Verlag Publishers: New York, 150172, 1998.
12. **Curley SA,** Jones DV. Hepatocellular carcinoma. In: Diagnosis and Staging of Neoplasms of the Digestive Tract. Lippincott/Raven Press: New York, 347-360, 1998.
13. Pollock RE, **Curley SA.** History of the University of Texas M. D. Anderson surgical training program. In: History of Medicine in Houston. Houston City Publishers: Houston, 28-52, 1998.
14. **Curley SA.** Surgical management of hepatocellular cancer. In: Liver Cancer. Springer Verlag Publishers: New York, 28-52, 1998.
15. Pearlstone DB, **Curley SA,** Feig BW. The management of gallbladder cancer before, during, and after laparoscopic cholecystectomy. In: Seminars in Laparoscopic Surgery. W.B. Saunders Publishers: New York, 121-128, 1998.
16. McMasters KM, **Curley SA.** Treatment of cholangiocarcinoma. In: Liver Cancer. Springer Verlag Publishers: New York, 95-116, 1998.
17. King T, **Curley SA.** Surgery. In: Physician Assistant: A Guide to Clinical Practice. W.B. Saunders: Orlando, 591-645, 1999.
18. Watkins KT, **Curley SA.** Liver and bile ducts. In: Clinical Oncology, Second Edition. Churchill Livingstone: New York, 1681-1748, 2000.
19. **Curley SA.** Neoplasms of the alimentary canal. Diagnosis and management of biliary tract cancer. In: Cancer Medicine, 5th. Ed(s) Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. B.C. Decker Publishers: Hamilton, Ontario, 1422-1430, 2000.

20. **Curley SA.** Neoplasms of the alimentary canal. The gallbladder. In: Cancer Medicine. Ed(s) 5th Edition. B.C. Decker Publishers: Hamilton, 1415-1421, 2000.
21. Barnett CC, **Curley SA.** Ablative techniques for hepatocellular carcinoma. In: Semin Oncol. 28, 487-496, 2001.
22. **Curley SA.** Diagnosis and management of intrahepatic and extrahepatic cholangiocarcinoma. In: Liver-Directed Therapy for Primary and Metastatic Liver Tumors. Kluwer Academic Publishers: Norwell, 117-144, 2001.
23. Izzo F, Barnett CC, **Curley SA.** Radiofrequency ablation of primary and metastatic malignant liver tumors. In: Advances in Surgery. Volume 35. Mosby Inc: St. Louis, 225-250, 2001.
24. Barnett CC, **Curley SA.** Ablation techniques, ethanol injection, cryoablation, and radiofrequency ablation. In: Operative Techniques in General Surgery. Volume 1, 4th Edition. Ed(s) Pinson CW. W.B. Saunders Company: Philadelphia, 65-75, 2002.
25. **Curley SA,** Cusack JC, Tanabe KK, Stoeltzing O, Ellis LM. Advances in the treatment of liver tumors. In: Current Problems in Surgery. 39, 5. Mosby Inc: St. Louis, 454571, 2002.
26. Parikh AA, **Curley SA,** Fornage B, Ellis LM. Radiofrequency ablation of hepatic metastases. In: Seminars in Oncology. 168-182. W.B. Saunders: Philadelphia, 2002.
27. Scaife CL, **Curley SA.** Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies. In: Primary and Metastatic Liver Cancer. Surgical Oncology Clinics of North America. 12, 1. Ed(s) Petrelli NJ, Vauthey JN. W.B. Saunders Company: Philadelphia, 243-255, 2003.
28. **Curley SA.** Gallbladder and bile duct cancer. In: Holland-Frei Cancer Medicine. Volume 2, 6th Edition. Ed(s) Kufe EW, Pollock RE, Weichselbaum RR, Bast RC, Holland JF, Frei E. B.C. Decker Inc.: Hamilton, 1569-1583, 2003.
29. Parikh AA, Fornage B, **Curley SA** and Ellis LM. Radiofrequency ablation of carcinoid and sarcoma liver metastases. In: Radiofrequency of Cancer: Current Indications, Techniques and Outcomes. Ed(s) Ellis LM, Curley SA, Tanabe KK. Springer-Verlag New York, Inc: New York, 107-120, 2003.
30. **Curley SA** and Izzo F. Radiofrequency ablation of hepatocellular carcinoma. In: Radiofrequency of Cancer: Current Indications, Techniques and Outcomes. Ed(s) Ellis LM, Curley SA, Tanabe KK. Springer-Verlag New York, Inc.: New York, 89-106, 2003.

30. **Curley SA.** Clinical aspects and management of cholangiocarcinoma and gallbladder carcinoma: Diagnostic and staging procedures. In: *Gastrointestinal Oncology*. Ed(s) Abbruzzese JL, Evans DB, Willett C, Fenoglio-Preiser C. Oxford University Press, Inc: New York, 436-453, 2004.
31. **Curley SA, Izzo F.** Colorectal cancer metastatic to the liver: Non-resective destructive techniques. In: *Current Surgical Therapy*. Ed(s) Cameron JL. Elsevier Mosby: Philadelphia, 341-352, 2004.
32. Tang Z-Y, **Curley SA.** Liver cancer. In: *The UICC Manual of Clinical Oncology, Eighth*. Ed(s) Pollock RE. International Union Against Cancer and John Wiley & Sons, Inc.: New York, 405-427, 2004.
33. Albo D, Wang T, **Curley SA.** Surgical management of liver metastases. In: *Advanced Therapy of Breast Disease*. Ed(s) Singletary SE, Robb GL, Hortobagyi, GN. BC Decker Inc.: Hamilton, 618-628, 2004.
34. **Curley SA, Izzo F, Abdalla E, Vauthey JN.** Surgical treatment of colorectal cancer metastasis. In: *Cancer and Metastasis Reviews*. Ed(s) Bresalier RS. Kluwer Academic Publishers: Norwell, 165-182, 2004.
35. Pawlik TM, **Curley SA.** Ethical issues in surgical palliative care: Am I killing the patient by letting him go? In: *Surg Clin North Am.* 85, 273-286, 2005.
36. **Curley SA, Sielaff TD.** Liver. In: *Schwartz's Principles of Surgery, Eighth Edition*. Ed(s) Brunickardi FC, Andersen DK, Billiar TF, Dunn DI, Hunter JG, Pollock RE. McGraw-Hill: New York, 1139-1186, 2005.
37. Waller MB, Beaty KA, McIntosh A, **Curley SA.** Staging of gastrointestinal malignancies. In: *M.D. Anderson Cancer Care Series: Gastrointestinal Cancer*. Ed(s) Ajani J, Janjan N, Lynch P, Curley SA. Springer Science & Business Media Inc: New York, 1-13, 2005.
38. Gannon CJ, **Curley SA.** The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors. In: *Semin Radiat Oncol.* 15. Ed(s) 4, 265-272, 2005.
39. **Curley SA.** Treatment of primary liver cancer. In: *M.D. Anderson Cancer Care Series: Gastrointestinal Cancer*. Ed(s) Ajani J, Janjan N, Lynch P, Curley SA. Springer Science & Business Media Inc.: New York, 197-218, 2005.
40. **Curley SA.** Gallbladder and bile duct cancer. In: *Holland-Frei Cancer Medicine. Volume 28, Seventh Edition*. Ed(s) Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E. B.C. Decker Inc: Hamilton, 1318-1330, 2006.

41. Delman KA, **Curley SA**. Hepatic neoplasms. In: Greenfield's Surgery. Scientific Principles and Practice, 4th Edition. Ed(s) Mulholland MW, Lillemoe KD, Doherty GM, Maier RV, Upchurch GR. Lippincott Williams & Wilkins: Philadelphia, 956977, 2006.
42. **Curley SA**. Surgical management of breast cancer liver metastases. In: Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches. Volume 26. Ed(s) Piccart M, Wood WC, Hung M-C, Solin LJ, Cardoso F. Springer: Heidelberg, 525-543, 2006.
43. **Curley SA** and Zager JS. Cancer radiofrequency ablation and other tissue ablative techniques. In: Mastery of Surgery 5th Edition. Ed(s) Fischer JE, Bland KI. Lippincott Williams and Wilkins: Philadelphia, PA, 180-188, 2006.
44. **Curley SA**. High malignant biliary tract obstruction. In: Mastery of Surgery, 5th Edition. Ed(s) Fischer JE, Bland KI. Lippincott Williams and Wilkins: Philadelphia, PA, 1165-1182, 2006.
45. **Curley SA**, Esnaola NF. Factors affecting morbidity and mortality after liver resection. In: Current Surgical Therapy, 9th Edition. Mosby Elsevier: Philadelphia, 366-372, 2008.
46. Gannon CJ, **Curley SA**. Hepatocellular cancer: Anatomy and staging. In: Principles and Practice of Gastrointestinal Oncology. Lippincott, Williams and Wilkins: Philadelphia, 429-435, 2008.
47. **Curley SA**. Surgical treatment of colorectal liver metastases. In: Advanced Therapy in Surgical Oncology. Ed(s) Pollock RE, Curley SA, Ross MI, Perrier ND. BC Decker Inc.: Hamilton, 104-112, 2008.
48. **Curley SA**, Izzo F. Surgical treatment of sarcoma liver metastases. In: Advanced Therapy in Surgical Oncology. Ed(s) Pollock RE, Curley SA, Ross MI, Perrier ND. BC Decker Inc.: Hamilton, 729-733, 2008.
49. Kaseb AO, Thomas MB, **Curley SA**. Gallbladder and bile duct cancer. In: Holland/Frei Cancer Edition, Eighth Edition. Ed(s) Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. BC Decker, 1132-1143, 2010.
50. Cherukuri P, **Curley SA**. Use of nanoparticles for targeted, noninvasive thermal destruction of malignant cells. In: Cancer Nanotechnology: Methods and Protocols. Ed(s) Grobmyer SR, Moudgil BM. Springer Science + Business Media: New York, 359-374, 2010.
51. Glazer ES, **Curley SA**. The ongoing history of thermal therapy for cancer. In: Ablative Procedures in Surgical Oncology. 20. W. B. Saunders: Philadelphia, PA, 229-235, 2011. PMID: 21377580

52. Glazer ES, **Curley SA**. Noninvasive RF ablation of malignancies mediated by quantum dots, gold nanoparticles, and carbon nanotubes. *Therapeutic Delivery*. 13251330, 2011.
 53. **Curley, SA**. Thermal cancer ablation therapies using nanoparticles. In: *Encyclopedia of Nanotechnology*. Springer. 2697-2704, 2012.
 54. Corr SJ, Raoof M, Wilson LJ, **Curley SA**. Nanoparticles for non-invasive radiofrequency-induced cancer hyperthermia. In: *Functional Nanoparticles for Bioanalysis, Nanomedicine and Bioelectronic Devices*. 1113. ACS Symposium Series, 81-94, 2012.
 55. Glazer ES, **Curley SA**. Liver cancer. In: *60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center*. Ed(s) Rodriguez MA, Walters RS, Burke TW. Springer Science and Business Media: New York, 167-175, 2013.
 56. Cooper AB, Aloia TA, Vathey JN, **Curley SA**. Controversies in Advance Disease – Surgical Approaches for Metastatic Resection. In *Colorectal Cancer: Diagnosis and Clinical Management*. Wiley & Sons LTD. 227-242, 2014.
 57. Sattler KD, **Curley SA**. Carbon nanomaterials sourcebook: Graphene, Fullerenes, and Nanodiamonds, Volume I. Ultrashort carbon nanocapsules for biomedicine. Taylor & Francis Group, CRC Press, 491-506, 2016
 58. Ho, J, **Curley SA**. Gastrointestinal Malignancies: Part of the series Cancer Treatment and Research. Springer. 121-163, 2016.
 59. **Curley SA**. Surgical approach to extrahepatic biliary tract cancer. In: *Atlas of Advanced Surgical Oncology*. Quality Medical Publishing: St. Louis. In Press.
 60. Glazer ES, **Curley SA**. Surgical management of hepatic metastases. In: *Advanced Therapy of Breast Disease*. Ed(s) F Esteva, R Skoracki, G Babiera G. BC Decker Inc.: Hamilton. In Press.
 61. Kaseb AO, Uemura M, Thomas MB, **Curley SA**. *Holland-Frei Cancer Medicine. Gallbladder and Bile Duct Cancer*. Ninth ed., John Wiley & Sons, Hoboken, New Jersey. 1115-1127, 2017.
 62. Mohammed S, **Curley SA**, Artinyan A. Hepato-Pancreato-Biliary and Transplant Surgery: Practical Management of Dilemmas: A patient with colorectal cancer and synchronous liver metastases: resect the primary first. *In press*
5. Other Works Communicating Research Results to Scientific Colleagues: Numerous lectures at meeting in the United States and around the world on Nanomedicine and Electromagnetic Field therapies.

6. Other Works Communicating Research Results to General Public: Numerous lectures at meeting in the United States and around the world on Nanomedicine and Electromagnetic Field therapies.

Letters to the Editor:

1. Evans DB, **Curley SA**. Use of EEA(R) stapler in reconstruction after gastric resection by Drs. Dewan, Hans, and Mittal. *Surg Gynecol Obstet* 169:347, 1989.
2. Evans DB, **Curley SA**. Letter to the Editor. *Surg Gynecol Obstet* 170:442, 1990.
3. Pollock RE, **Curley SA**, Lotzova ES. A short course in research ethics for trainees. *Acad Med* 69:213-214, 1994.
4. **Curley SA**. Review of paper: Hepatic colorectal metastases: current status of surgical therapy. *Oncology* 12:1500, 1998.
5. **Curley SA**, Izzo F. Laparoscopic radiofrequency. *Ann Surg Oncol* 7:78-79, 2000.
6. Vauthey J-N, Pawlik TM, Lauwers GY, Nagorney DM, Roh MS, **Curley SA**, Poon RT, Belghiti J, Greene F, Henderson JM. Critical evaluation for the different staging systems for hepatocellular carcinoma. *Br J Surg* 91:1072, 2004.
7. **Curley SA**. Book review of progress in colorectal surgery by Benyon J, Carr ND. *Cancer Investigation* 24:1-2, 2006.
8. Ellis, LM, **Curley SA**, Grothey A. In reply. *J Clin Oncol* 24:2593-2594, 2006.
9. **Curley SA**. Radiofrequency ablation versus resection for resectable colorectal liver metastases: Time for a randomized trial? *Annals of Surgical Oncology* 15:11-13, 2007.

Manuals, Teaching Aids, Videos, Other Teaching Publications:

1. **Curley SA**. Resection of cholangiocarcinoma following preoperative intralesional matrixplatinum injection. Video presented at the Italian Society of Surgical Oncology Meeting, Naples, Italy, 9/1993.
2. **Curley SA**, Lee JE, Chase J, Collier, C. Liver resection for gallbladder carcinoma following intratumoral matrix-cisplatin injections. Video presented at the Society of Surgical Oncology Meeting, Houston, Texas, 3/1994.
3. Skibber J, Hunt K, **Curley SA**. The Kraske procedure for rectal cancer. Video presented at The American College of Surgeons Meeting, New Orleans, Louisiana, 10/1995.
4. **Curley SA**. Subtotal gastrectomy for gastric leiomyosarcoma. Video presented at the European Congress of Surgeons Meeting, Naples, Italy, 12/1996.

5. **Curley SA.** Upper gastrointestinal cancer. Slide set and course syllabus for the American College of Surgeons Commission on Cancer Meeting, 1996.
6. **Curley SA,** Izzo F. Radiofrequency ablation of primary and metastatic liver cancers. Video presented at Society of Surgical Oncology Meeting, New Orleans, Louisiana, 3/2000.
7. Abdalla EK, Barnett CC, **Curley SA.** Orthotopic liver transplantation for hepatocellular carcinoma. UpToDate.com, 2001.
8. **Curley SA.** Other ways to treat liver cancer. YourDoctor.com, 2001.
9. **Curley SA,** Barnett CC, Abdalla EK. Staging and prognostic factors in hepatocellular carcinoma. UpToDate.com, 2001.
10. Barnett CC, Abdalla EK, **Curley SA.** Surgical management of hepatocellular carcinoma. UpToDate.com, 2001.
11. **Curley SA,** Minsky B. Multidisciplinary management in patients presenting with resectable or borderline-resectable stage IV colorectal cancer. 4. Oncology Consultants, 110, 2007.
12. **Curley SA,** Alberts SR, Saltz LB, Jain RK. Colorectal cancer update. Conversations with oncology investigators. Bridging the gap between research and patient care. 7, 3. Ed(s) Love N. Research to Practice: Miami, 2008.
13. Glazer ES, **Curley SA.** Technical aspects of hepatic resection. UpToDate, Inc. 2015.

D. Innovation and Commercialization

1. Patents

BLG Number Application Type Application Serial Number Filing Date

14-077 & 15-001	US Provisional	62/028,604	7/24/2014
14-077 & 15-001	PCT	PCT/US2015/042118	7/24/2015
15-037	US Provisional	62/131,123	3/10/2015
15-037	US Utility	15/067,010	3/10/2016
15-083	US Provisional	62/335,759	5/13/2016
16-006	US Provisional	62/401,795	9/29/2016
16-030	US Provisional	62/239,708	10/9/2015
16-030	PCT	Unavailable yet	10/06/2016
17-010	US Provisional	62/312,579	03/24/2016

2. Device, software, or other development: CorleyWare Device to provide local RF-induced hyperthermia to vessels (like the superior mesenteric artery) or other structures where a cancer free resection margin is not feasible but where local tumor control is critical.
3. Other activities: numerous invention disclosure reports and provisional patents related to nanomaterial delivery of cytotoxic or immunotherapy agents for malignant disease; intracellular temperature sensitive molecules; or novel electromagnetic field devices to enhance intra-tumoral blood flow and overcome barriers to delivery of cancer therapeutic agents and cells.

TEACHING INFORMATION

A. Didactic Coursework

1. Weekly didactic lectures and patient case studies for BCM surgical residents and students every Wednesday at BSLMC

Department of Surgery Grand Rounds: Hilar Cholangiocarcinoma September 2016

2. Courses Taught at Baylor College of Medicine External to the Primary Department: TBMM lectures to graduate students on role of translational research in surgical and cancer care, lecture given twice yearly.

3. Courses Taught

- GME Core Curriculum Lecture Series. Research Ethics for all Fellows, The University of Texas M D Anderson Cancer Center, 1996-2012
- Profiles of Science, Faculty Development, Academic Programs, The University of Texas M D Anderson Cancer Center, 9/2001
- Course Director, Advanced Course in RF Ablation and Imaging, The University of Texas M D Anderson Cancer Center, 2002
- Physician Scientist Training Program, 2004-2006
- Course Director, Clinical Research Module for Surgical Oncology Fellows, The University of Texas M D Anderson Cancer Center, 2004
- Course Director, Surgical Education: Enhancing Teaching Skills in and out of the O.R., The University of Texas M D Anderson Cancer Center, 2/2005

B. Curriculum Development Work (include institution where work was done)

1. First Annual BCM Department of Surgery Surgical Oncology/General Surgery Update
Co-Director along with Dr. Bill Fisher
Surgeons, Gastroenterologists, and Medical Oncologists in the Houston area

C. Non-didactic Teaching

1. Resident and Fellow Training at MD Anderson and Baylor College of Medicine (>20 hours/week)
2. Clinical Fellow Training (include names of fellows, dates)
 - Director, Surgical Oncology Fellowship Program, University of Texas MD Anderson Cancer Center, 1/1990 – 9/2009
 - The University of Texas M D Anderson Cancer Center
 - Dr. Grant Carlson, 7/1988-6/1991
 - Dr. Jean Couture, 7/1988-6/1991
 - Dr. Patrick Whitworth, 7/1988-6/1991
 - Dr. Paul Mansfield, 7/1988-6/1991
 - Dr. Charles Shumate, 7/1989-6/1991
 - Dr. Mary Rippon, 7/1989-6/1991
 - Dr. David Byrd, 7/1989-6/1992
 - Dr. Mark Talamonti, 7/1989-6/1992
 - Dr. George Daneker, 7/1990-6/1992
 - Dr. Jeffrey Lee, 7/1990-6/1992
 - Dr. Lee Ellis, 7/1990-6/1992
 - Dr. Timothy Yeatman, 7/1990-6/1992
 - Dr. George Barnes, 7/1990-6/1993
 - Dr. Kenneth Tanabe, 7/1990-6/1993
 - Dr. Marc Demers, 7/1990-6/1993
 - Dr. Michael Khaky, 7/1991-6/1993
 - Dr. Barry Feig, 7/1991-6/1994
 - Dr. David Berger, 7/1991-6/1994
 - Dr. George Fuhrman, 7/1991-6/1994

Dr. James Reilly, 7/1991-6/1994

Dr. Davis Winchester, 7/1992-6/1994

Dr. Sarkis Meterissian, 7/1992-6/1994

Dr. Alan Yahanda, 7/1992-6/1995

Dr. Charles Staley, 7/1992-6/1995

Dr. James Cusack, 7/1992-6/1995

Dr. Steven Leach, 7/1993-6/1995

Dr. Andrew Lowy, 7/1993-6/1996

Dr. Derrick Beech, 7/1993-6/1996

Dr. Gregory Midis, 7/1993-6/1996

Dr. Scott Davidson, 7/1993-6/1996

Dr. Phillip Ley, 7/1993-6/1996

Dr. Kelly Hunt, 7/1994-6/1996

Dr. Kelly McMasters, 7/1994-6/1996

Dr. Todd Tuttle, 7/1994-6/1996

Dr. Willilam Thompson, 7/1994-6/1996

Dr. Declan Fleming, 7/1994-6/1997

Dr. Francis Spitz, 7/1994-6/1997

Dr. Barry Roseman, 7/1995-6/1997

Dr. Jeffrey Sussman, 7/1995-6/1997

Dr. Michael Bouvet, 7/1995-6/1998

Dr. Paul Ahearne, 7/1995-6/1998

Dr. Paul Termuhlen, 7/1995-6/1998

Dr. Alexander Miller, 7/1996-6/1998

Dr. David Pearlstone, 7/1996-6/1998

Dr. George Peoples, 7/1996-6/1998

Dr. Keith Heaton, 7/1996-6/1998

Dr. Richard Bold, 7/1996-6/1998

Dr. Jason Fleming, 7/1997-6/1999

Dr. Lisa Newman, 7/1997-6/1999

Dr. Scott Pearson, 7/1997-6/1999

Dr. Charles Portera, 7/1997-6/2000

Dr. Christine Laronga, 7/1997-6/2000

Dr. Russell Berman, 7/1997-6/2000

Dr. Tara Breslin, 7/1997-6/2000

Dr. Alan Dackiw, 7/1998-6/2000

Dr. Geoffrey Porter, 7/1998-6/2000

Dr. John Ehrenfried, 7/1998-6/2000

Dr. Malcom Bilimoria, 7/1998-6/2000

Dr. Meric Funda, 7/1998-6/2001

Dr. Syed Ahmad, 7/1998-6/2001

Dr. Ana Grau, 7/1999-6/2001

Dr. Carlton Barnett, 7/1999-6/2001

Dr. Jeffrey Lenert, 7/1999-6/2001

Dr. Thomas Wang, 7/1999-6/2001

Dr. Wayne Jeffrey, 7/1999-6/2001

Dr. Daniel Albo, 7/1999-6/2002

Dr. Eddie Abdalla, 7/1999-6/2002

Dr. Janice Cormier, 7/1999-6/2002

Dr. Carmen Solorzano, 7/2000-6/2002

Dr. Hiroomi Tada, 7/2000-6/2002

Dr. Rosario Hwang, 7/2001-6/2003

Dr. Alexander Parikh, 7/2001-6/2003

Dr. Courtney Scaife, 7/2001-6/2003

Dr. Dennis Rousseau, 7/2001-6/2003

Dr. Lee Pederson, 7/2001-6/2003

Dr. Nestor Esnaola, 7/2001-6/2003

Dr. Richard Royal, 7/2001-6/2003

Dr. Wayne Frederick, 7/2001-6/2003

Dr. David Smith, 7/2001-6/2004

Dr. Isabelle Bedrosian, 7/2001-6/2004

Dr. Chan Raut, 7/2002-6/2004

Dr. Charles Scoggins, 7/2002-6/2004

Dr. Richard Ehlers, 7/2002-6/2004

Dr. Tina Yen, 7/2002-6/2004

Dr. Timothy Pawlik, 7/2002-6/2005

Dr. Todd Bauer, 7/2002-6/2005

Dr. Jennifer Tseng, 7/2003-6/2005

Dr. John Mullen, 7/2003-6/2005

Dr. Keith Delman, 7/2003-6/2005

Dr. Thomas Aloia, 7/2003-6/2005

Dr. Laura Lambert, 7/2003-6/2006

Dr. Robert Andtbacka, 7/2003-6/2006

Dr. Jonathan Zager, 7/2004-6/2006

Dr. Steven Rodgers, 7/2004-6/2006

Dr. Waddah Al-Rafaie, 7/2004-6/2006

Dr. Christopher Gannon, 7/2004-6/2007

Dr. Eugene Choi, 7/2004-6/2007

Dr. Keith Amos, 7/2004-6/2007

Dr. Ricardo Gonzalez, 7/2004-6/2007

Dr. Brian Badgwell, 7/2005-6/2007

Dr. Keith Gray, 7/2005-6/2007

Dr. Ramsay Camp, 7/2005-6/2007

Dr. Susan Kesmodel, 7/2005-6/2007

Dr. Curtis Wray, 7/2005-6/2008

Dr. Elizabeth Mittendorf, 7/2005-6/2008

Dr. Sherry Lim, 7/2005-6/2008

Dr. Dan Blazer, 7/2006-6/2008

Dr. Daniel Anaya, 7/2006-6/2008

Dr. Elizabeth Grubbs, 7/2006-6/2008

Dr. Mathew Katz, 7/2006-6/2008

Dr. Melinda Mortenson, 7/2006-6/2008

Dr. Keith Fournier, 7/2006-6/2009

Dr. Yun Shin Chun, 7/2006-6/2009

Dr. C. Denise Ching, 7/2007-6/2009

Dr. Joshua Mammen, 7/2007-6/2009

Dr. Kerrington Smith, 7/2007-6/2009

Dr. Sharon Chang, 7/2007-9/2009

Dr. Abigail Caudle, 7/2007-6/2010

Dr. Debashish Bose, 7/2007-6/2010

Dr. Glenda Callender, 7/2007-6/2010

Dr. Carlo Contreras, 7/2008-6/2010

Dr. Eric Silberfein, 7/2008-6/2010

Dr. Richard Berri, 7/2008-6/2010

Dr. Tawnya Bowles, 7/2008-6/2010

Dr. Christine Landry, 7/2008-6/2011

Dr. Keila Torres, 7/2008-6/2011

Dr. Priscilla McAuliffe, 7/2008-9/2011

Dr. Anthony Yang, 7/2009-6/2011

Dr. Cary Hsu, 7/2009-6/2011

Dr. David Kwon, 7/2009-6/2011

Dr. John Abad, 7/2009-6/2011

Dr. Julia Veerapong, 7/2009-6/2011

Dr. Mark Truty, 7/2009-6/2012

Dr. Paxton Dickson, 7/2009-6/2012

Dr. Daniel Abbott, 7/2010-6/2012

Dr. John Hyngstrom, 7/2010-6/2012

Dr. Joshua Hill, 7/2010-6/2012

Dr. Maria Russell, 7/2010-6/2012

Dr. Robert Roses, 7/2010-6/2012

Dr. Ching-Wei Tzeng, 7/2010-6/2013

Dr. Ryan Thomas, 7/2010-6/2013

Dr. Alex Haynes, 7/2011-6/2013

Dr. Brian Bednarski, 7/2011-6/2013

Dr. Nikolaos Dallas, 7/2011-6/2013

Dr. Sukhyung Lee, 7/2011-6/2013

Dr. Vance Sohn, 7/2011-6/2013

Dr. Amanda Cooper, 7/2011-12/2013

Dr. Christina Roland, 7/2011-12/2013

Dr. Genevieve Boland, 7/2011-12/2013

Dr. William Tseng, 7/2011-12/2013

Dr. Aviad Hoffman, 7/2012-12/2013

Dr. Christina Bailey, 7/2012-12/2013

Dr. Michael Kim, 7/2012-12/2013

Dr. Nader Massarweh, 7/2012-12/2013

Dr. Natasha Reuth, 7/2012-12/2013

Dr. Warren Tseng, 7/2012-12/2013

Dr. William Burns, 7/2012-12/2013

Dr. Andre Libawi, 7/2013-12/2013

Dr. Callisia Clarke, 7/2013-12/2013

Dr. Chee-Chee Stucky, 7/2013-12/2013

Dr. Joe Liles, 7/2013-12/2013

Dr. Nicole de Rosa, 7/2013-12/2013

Dr. Sean Dineen, 7/2013-12/2013

Dr. Wayne Orr, 7/2013-12/2013

Dr. Hop Tran Cao, 7/2012-2013

3. Graduate Student Training: for the trainees listed above I was the Surgical Oncology Fellowship Program Director, responsible for designing and implementing all clinical rotations, didactic course work, and nonsurgical rotations and research activities. For the trainees listed below, I have been a primary laboratory advisor/mentor and a member of their thesis committee.

- Rice University

Matthew Cheney, 2007-2014

Sophia Phounsavath, 2007-2014

Justin Law, 2011-2014

Tawana Robinson, 2013-2014

Nicholas Zaibaq, 2013 - 2017

Nadia Lara 2013-2016

Mayra Hernandez, Mayra, 2014 – 2017

Trever Jamison, 2014 – 2017

Asad Haider, 2015 – 2017

Sanchit Sachdeva, 2015 – 2017

- UT Health Science Center Houston

Jonathan Martinez, 2011-2015

- UT Graduate School of Biomedical Sciences David Savage, 2009-2015

- UT Houston Medical School

Jonathan Vo, 2013-2014

Medical Student Mentoring: I have had a total of 7 4th Year student sub interns on my service, I've worked with them daily, provided real-time feedback and advice, and written letters of recommendation for General Surgery Training Programs.

Other Formal Training/Teaching Duties:

The University of Texas M D Anderson Cancer Center

- Monthly didactic sessions with residents and students, 1990-2013
- Surgery Grand Rounds, 7/1991, 4/1995, 7/1995, 9/1997, 7/1998, 6/1999, 1/2003, Institutional Grand Rounds, 10/1998, 2/2000, 6/2002, 5/2003, 8/2007,

- Surgical Issues in Clinical Trial Design, The Physician-Scientist Training Program, 5/2002
- Colorectal Multidisciplinary Conference, 7/2002
- Nutrition Support Grand Rounds, 2/2003
- Medical Oncology Didactic Lecture Series, 11/2003, 1/2004, 8/2004
- Multidisciplinary Gynecologic Oncology Conference, 1/2004 • Melanoma Translational Objectives Meeting, 11/2004

D. Lectures and Presentations

Seminar Invitations from Other Institutions:

- Surgical treatment of hepatic malignancies, Northwestern University's Annual Clinical Science, Chicago, IL, 4/1/2000
- Colorectal cancer liver metastases: Is four still the limit for surgical treatment, Perspectives in Colorectal Cancer Meeting, Miami, FL, 9/1/2001.
- Emerging trends in the management of colorectal cancer, Health Science Center for Continuing Medical Education, Enid, OK, 1/5/2006.
- Technologic Innovations in the Operating Room, The G. Pascale National Cancer Institute, Naples, Italy, 4/2006
- The VEGF pathway as a therapeutic target in cancer, Nevada Cancer Institute, Las Vegas, NV, 7/2007
- Bio nanotechnology in cancer care, Qatar Foundation/M. D. Anderson Cancer Center, Doha, Qatar, 1/2009
- Future uses of nanotechnology in cancer treatment, 15th International Symposium: Gastrointestinal Malignancies, King Hussain Cancer Center, Amman, Jordan, 3/2009
- Management of hepatocellular carcinoma, 15th International Symposium: Gastrointestinal malignancies, King Hussain Cancer Center, Amman, Jordan, 3/2009
- Nanoparticles and focused RF energy to treat hepatocellular cancer, The G. Pascale National Cancer Institute, Naples, Italy, 3/2009
- Targeted nanoparticles and RF-induced thermal destruction of cancer cells, Nanobiotechnology Seminar Series, Stanford School of Medicine, Stanford, CA, 8/2009
- Innovations in nanotechnology and a future role in liver directed therapy for primary and metastatic tumors, Northshore University Health System, Chicago, IL, 10/2009
- Advances in Cancer Management for the Surgeon. Multiple colorectal carcinoma liver metastases: Surgical strategies to be more aggressive, Harvard Medical School, Boston, MA, 11/2009

- Advances in Cancer Management for the Surgeon. Hepatocellular carcinoma: Resect, ablate or transplant, Harvard Medical School, Boston, MA, 11/2009
- Targeted nanoparticles for non-invasive hyperthermia in malignant disease, Sao Paulo School of Advanced Studies, Sao Paulo, Brazil, 2/2013.
- Surgical treatment of metastatic GI cancers to the liver, University of Arkansas for Medical Sciences, Little Rock, AR, 3/2012.

Other Presentations at State and Local Conferences:

- Grand Rounds, St. Joseph's Hospital, Houston, TX, 3/1991
- Grand Rounds, St. Joseph's Hospital, Houston, TX, 11/1991
- Surgery Grand Rounds, Baylor College of Medicine, Houston, TX, 2/1993
- Grand Rounds, Clinical Congress of Abdominal Surgeons, Houston, TX, 4/1994
- Grand Rounds, Texas Radiological Society, Austin, TX, 4/1994
- Surgery Grand Rounds, Baylor College of Medicine, Houston, TX, 7/1994
- Surgery Grand Rounds, Baylor College of Medicine, Houston, TX, 12/1998
- RF ablation of malignant liver tumors, Multidisciplinary treatment of patients with GI malignancies, Willford Hall Air Force Hospital, San Antonio, TX, 4/2001
- Update on hepatocellular cancer and hepatitis, UT Health Science Center at Houston Medical School, Houston, TX, 5/2002
- Colorectal Cancer Liver Metastases: Is Four Still the Limit for Surgical Treatment, The 23rd Annual Pharmacy Symposium on Cancer Chemotherapy, UT M. D. Anderson Cancer Center, Houston, TX, 10/2003
- Outcomes with surgical management of primary and metastatic hepatic malignancies, The 19th

Annual William D. Seybold, M.D. Lectureship in Surgery, University of Texas Southwestern Medical Center, Dallas, TX, 10/2003

- Primary hepatobiliary tumor therapy, Oncologic Interventional Radiology Symposium, Houston, TX, 1/2004
- Emerging trends in the management of colorectal cancer, Laredo Medical Center, Laredo, TX, 8/2006
- New therapies for primary and metastatic liver cancer: Surgical treatment of primary and metastatic liver tumors, Citizen's Medical Center, Victoria, TX, 12/2006

- Nanoparticles as intracellular targets to produce RF-induced thermal destruction of cancer cells, Alliance for NanoHealth Brunch Meeting, Houston, TX, 2/2007
- Nanoparticles as cancer therapeutic agents, Institutional Grand Rounds, UT M. D. Anderson Cancer Center, Houston, TX, 7/2007
- Nanoparticles as targets for RF thermotherapy in cancer, The Methodist Hospital, Weill Cornell Medical College, Houston, TX, 6/2008
- Nanotechnology applications in medical care, Summer Professional Student Nurse Extern Program, UT M. D. Anderson Cancer Center, Houston, TX, 7/2008
- Twenty years of pushing the envelope, Tumor Conference, Trinity Mother Frances Hospitals and Clinics, Tyler, TX, 7/15/2008
- Targeted gold nanoparticles for noninvasive RF thermal cytotoxicity, Multidisciplinary Colorectal Cancer Clinical Translational Research Conference, UT M. D. Anderson Cancer Center, TX, 12/8/2008
- Surgical treatment of colorectal liver metastases, Louisiana Chapter American College of Surgeons, New Orleans, LA, 1/17/2009
- Surgical options for hepatocellular cancer, Louisiana Chapter American College of Surgeons, New Orleans, LA, 1/18/2009
- Current and future therapies for liver tumors, Department of Surgery Grand Rounds, University of Texas Health Science Center at Houston Medical School, Houston, TX, 2/12/2009
- Thermal therapy for Cancer, Nanotech Conference and Expo, Houston, TX, 5/2009
The Past, Present and Future (?) of Treatment for Colorectal Liver Metastases, Surgery Grand Rounds, The Methodist Hospital System, Houston, TX, 6/2009
- An overview of surgical oncology, GME Core Curriculum Lecture Series, UT M. D. Anderson Cancer Center, Houston, TX, 7/2009
- Nanotechnology applications in cancer diagnosis and treatment, Surgical Oncology Grand Rounds, UT M. D. Anderson Cancer Center, Houston, TX, 7/2009
- Nanotechnology in medical and cancer care: How things really small are going to be big!, Making Cancer History Symposium, UT M. D. Anderson Cancer Center, Aspen, CO, 7/2009
- Radiofrequency nanotechnology noninvasive cancer treatment, Summer Student Nurse Intern Lecture, UT M. D. Anderson Cancer Center, Houston, TX, 7/2009
- Thermal Therapies for HCC, HIRG Meeting, UT M. D. Anderson Cancer Center, Houston, TX, 1/2010
- IOM Recommendations, The Division of Surgery Grand Rounds, UT M. D. Anderson Cancer Center, 2/2010

- Surgical approaches in the treatment of colon cancer, Hendrick Cancer Center, Abilene, TX, 11/2010
- EMR - based hyperthermia to treat cancer, 3rd Annual IMM Student and Post-Doc Research Retreat, UT Health Science Center at Houston, Houston, TX, 6/2013
- Injectable delivery of agents into liver tumors, Uveal Melanoma Assembly, UT M. D. Anderson Cancer Center, Houston, TX, 7/2013
- BSLMC Foundation – Guiding Stars Medical Panel, Houston, TX, 9/2015.
- Biology and Treatment of Hilar Cholangiocarcinoma, Department of Surgery Grand Rounds, Baylor College of Medicine, Houston, TX, 9/2016.

Organization of Conferences/Symposia (Including Chairing Sessions):

- The G. Pascale National Cancer Institute, Advanced Course in RF Ablation and Imaging, Naples, Italy, Course Director, 1/2001
- World Federation of Surgical Oncology Societies, Second International Meeting, Organizing Committee, Naples, Italy, Member, 1/2001
- World Federation of Surgical Oncology Societies, Second International Meeting, Naples, Italy, Organizing Committee, 9/2001
- The University of Texas MD Anderson Cancer Center, Multidisciplinary Management of Gastrointestinal Malignancies, Maui, HI, Course Director, 2/2002
- XV Congress of the SPIGC, Vibo Valentia, Italy, President of the English Session, 6/2002
- American Society of Clinical Oncology Annual Meeting, Gastrointestinal cancer, Chicago, IL, Chair, 6/2003
- American College of Surgeons Annual Clinical Congress, Thermal ablation of malignant tumors - too hot to handle, Chicago, IL, Moderator, 10/2003
- 6th World Congress of the International Hepato-Pancreato-Biliary Association, Transection techniques, New York, NY, Chair, 6/2004
- 5th International Hepatocellular Carcinoma. Eastern and Western Experiences Conference, Free papers, Houston, TX, Chair, 1/2007
- American Society of Clinical Oncology, Gastrointestinal Cancer Symposium, San Francisco, CA, Member, Steering Committee, 1/2009
- American Society of Clinical Oncology, Education Session, Orlando, FL, Chair, 6/2009
- American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, Orlando, FL, Member, Steering Committee, 1/2010
- UT M. D. Anderson Cancer Center, Division of Surgery Grand Rounds, Houston, TX, Moderator, 2/2010

- UT M. D. Anderson Cancer Center, Center for Biological Pathways and GI Cancers Joint Retreat, Houston, TX, Moderator, 11/2010

American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, San Francisco, CA, Chair, Steering Committee, 1/2011
- National Cancer Institute, Second Annual Physical Sciences - Oncology Centers (PS-OCs) Network Investigators' Meeting, San Diego, CA, Moderator, 4/2011
- 9th Annual American College of Surgeons Clinical Congress. Minimally invasive therapies for hepatic malignancies: Ready for prime time? San Francisco, CA, Moderator, 10/2011
- 2012 GI ASCO Cancers Symposium, Cancers of the colon and rectum: Multidisciplinary treatment, San Francisco, CA, Chair, 1/2012
- University of Texas M. D. Anderson Cancer Center, Division of Surgery Grand Rounds, Houston, TX, Moderator, 5/2012
- 10th World Congress of the International Hepato-Pancreato-Biliary Association, Nonsurgical/Non-ablative treatments of HCC Session, Paris, France, Chair, 7/2012
- G. Pascale Site Visit, Naples, Italy, 6/6 – 6/21/2015
- European Society Surgical Oncology, Italy, 9/8-9/13/2015
- BSLMC Embassy UAE Medical Team, Washington, DC, 10/21 – 10/23/2015
- BSLMC Embassy Oncology Service Line, Congreso Oncologia al Limite III, Guadalajara, Mexico, 11/5 – 11/6/2015

Other, Including Scientific Exhibitions:

- Moderator, Thermal ablation of malignant tumors - too hot to handle? American College of Surgeons Annual Clinical Congress, Chicago, IL, 10/1/2003
- Moderator, Expanding procedures for surgical oncologists, The Society of Surgical Oncology Cancer Symposium, New York, NY, 3/1/2004.
- Case Presentations: Pancreas/Liver, 7th Annual Oncology Update: Advances and Controversies, Steamboat Springs, CO, 1/2007
- Surgical oncology - Outcomes after resection or ablation of colorectal liver metastases, Canadian Society of Surgical Oncology, Victoria, British Columbia, Canada, 9/2009
- Technical tips and challenges in liver resection, Canadian Society of Surgical Oncology, Victoria, British Columbia, Canada, 9/2009
- Making decisions for the patient with hepatocellular carcinoma: Resection, transplantation, intra-arterial therapy or nexavar?" Academic Surgical Congress and Society of University Surgeons, San Antonio, TX, 2/2010

- Where's Waldo? Non-invasive radiofrequency field induced thermal destruction of human malignant cells, First Annual NCI Physical Sciences - Oncology Network Investigators' Meeting, National Harbor, MD, 4/2010
- Surgical approaches to hepatic neoplasia: Challenges and opportunities, Gastrointestinal Malignances: Endoscopic, Surgical and Oncologic Approaches in 2010, San Juan, PR, 8/2010
- Role of metastectomy for colorectal cancer, Sixth Annual Chicago Supportive Oncology Conference, Chicago, IL, 10/2010
- Non-Invasive radiofrequency heating of targeted nanoparticles to kill pancreatic and liver cancers. Materials Research Society, MRS Fall Meeting Symposia, Boston, MA, 12/2014
- Resection of colorectal liver metastases: still the standard of care? The University of Texas MD Anderson Cancer Center, 13th Oncology Update: Advances and Controversies. Steamboat Springs, CO. 1/2015

E. Visiting Professorships (include location, dates, lectures)

- Targeted nanoparticles for non-invasive hyperthermia in malignant disease, Sao Paulo School of Advanced Studies, Sao Paulo, Brazil, 2/2013
- Grand Rounds, Orlando Regional Medical Center, Orlando, FL, 4/1991
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 6/1992
- Grand Rounds, Medical College of Ohio, Toledo, OH, 9/1992
- Grand Rounds, Maine Medical Center, Portland, ME, 9/1993
- Rounds Grand, Roswell Park Memorial Cancer Center, Buffalo, NY, 10/1993
- Grand Rounds, Cleveland Clinic, Cleveland, OH, 4/1994
- Grand Rounds, Wright State University, Dayton, OH, 9/1994
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 5/1995
- Grand Rounds, St. Luke's International Hospital, Tokyo, Japan, 6/1995
- Medical Rounds, Orlando Regional Medical Center, Orlando, FL, 9/1995
- Grand Rounds, Medical Center East Hospital, Birmingham, AL, 10/1995
- Grand Rounds, The National Cancer Institute of Italy, Rome, Italy, 12/1995
- Grand Rounds, The National Cancer Institute of Portugal, Portugal, 5/1996
- Grand Rounds, The University of Catania, Catania, Italy, 6/1996
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 6/1996

- Grand Rounds, The University of Melbourne, Peter McCallum Cancer, Melbourne, Australia, 12/1996
- Grand Rounds, The University of Naples, Naples, Italy, 12/1996
- Current Concepts in General Surgery, The University of New Mexico, Albuquerque, NM, 7/1997
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 12/1997
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 1/1998
- Grand Rounds, The University of Cairo Egyptian National Cancer C, Cairo, Egypt, 4/1999
- Grand Rounds, The University of Texas Southwestern Medical School, Dallas, TX, 5/1999
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 3/2000
- Grand Rounds, Penn State Medical Center, Hershey, PA, 4/2000
- Grand Rounds, Federico I. Università di Napoli, Naples, Italy, 6/1/2000
- Grand Rounds, Paul Brousse Hepatobiliary Institute, Villejuif, Paris, France, 10/2000
- Grand Rounds, Free University of Brussels, Brussels, Belgium, 10/2000
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 1/2001
- Current surgical and local treatment options for hepatocellular cancer, Medical Rounds, Orlando Regional Medical Center, Orlando, FL, 3/1/2001
- Grand Rounds, University of Minnesota, Minneapolis, MN, 11/2001
- Grand Rounds, Medical University of South Carolina, Charleston, SC, 12/2001
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 6/2002
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 11/2002
- Surgical treatment of hepatic malignancies, Surgical Grand Rounds, Christiana Care Health Services, Newark, DE, 1/2003
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 4/2004
- Grand Rounds, Temple University School of Medicine, Philadelphia, PA, 9/2004
- Outcomes after surgical treatment of colorectal cancer liver metastases, Temple University School of Medicine, Philadelphia, PA, 9/2004
- Surgical treatment of primary and metastatic liver tumors, Medical College of Ohio, Toledo, OH, 2/2005

- Surgical management of liver metastases, Norton Healthcare and University of Louisville, Louisville, KY, 3/2005
- Surgical management of malignant liver tumors, Toronto General Hospital and The Critical Care Society, Toronto, Canada, 3/2005
- Surgical management of primary rectal cancer, Norton Healthcare and University of Louisville, Louisville, KY, 3/2005
- Multimodality treatment of colorectal metastases, Presbyterian Hospital, Tumor Board, Charlotte, NC, 4/2005
- Multimodality treatment of hepatic malignancies, Carolinas Medical Center, Charlotte, NC, 4/2005
- Outcomes after surgical treatment of colorectal cancer liver metastases, Saint Francis Hospital and Medical Center, Hartford, CT, 1/2006
- Grand Rounds, The G. Pascale National Cancer Institute, Naples, Italy, 4/2006
- Outcomes after surgical treatment of colorectal cancer liver metastases, Grand Rounds, University of New Mexico School of Medicine, Albuquerque, NM, 4/2006
- Outcomes after surgical treatment of colorectal cancer liver metastases, Grand Rounds, Georgetown University Hospital, Washington, DC, 5/2006
- Nanoparticles as intracellular resonant antennae to produce RF-induced thermal destruction, Grand Rounds, Cross Cancer Institute, Edmonton, Alberta, Canada, 12/2006
- The VEGF pathway as a therapeutic target in cancer, University of Tennessee Graduate School of Medicine, Knoxville, TN, 10/2007
- A night of discovery: Sending cancer a signal, Lee Memorial Health System, Fort Myers, FL, 3/2008
- Standard of care of metastatic colorectal cancer: Still a shifting paradigm, Integris Southwest Medical Center, Oklahoma City, OK, 3/2008
- Grand Rounds. Surgical treatment of colorectal liver metastases, Steven J. Moses Memorial Lectureship, Good Samaritan Hospital, Cincinnati, OH, 4/11/2008
- Present and future treatment of colorectal cancer liver metastases, UMass Memorial Medical Center, Worcester, MA, 6/2009
- Nanotechnology in medical and cancer care: How things really small are going to be big! MDACC Educational Event, University of Texas M. D. Anderson Cancer Center, Aspen, CO, 7/2009
- Treatment of hepatocellular cancer, Surgery Grand Rounds, University of Massachusetts, Worcester, MA, 9/2009

- Targeted nanoparticles for non-invasive RF treatment of malignant disease, MCG Cancer Center, Augusta, GA, 8/2010
- Nanotechnology as a novel cancer therapy, The Future of Surgical Oncology. A Festschrift in Honor of Charles M. Balch, MD, FACS, John Hopkins Department of Surgery, Baltimore, MD, 5/2011
- Use of novel therapies in cancer treatments, Stony Brook University Medical Center, Stony Brook, NY, 6/2011
- Non-invasive RF-induced hyperthermia to treat malignant tumors, 2012 Scholarly Research Project Seminar Series of the Department of NanoMedicine and BioMedical Engineering, The Education and Outreach Program of the NCI's Texas Center for Cancer NanoMedicine, and the Translational Technologies Core of the Center for Clinical and Translational Sciences, The University of Texas Health Science Center at Houston, Houston, TX, 8/2012
- Current and future treatment of hepatic malignancy, Surgical Grand Rounds, Robert Wood Johnson Medical School, New Brunswick, NJ, 12/2012
- Current and future treatment of hepatic malignancy, Surgical Grand Rounds, Beth Israel Medical Center, Department of Surgery, New York, NY, 1/2013
- Ohio State University Wexner Medical Center Surgery Grand Rounds, Columbus, Maximally Invasive to Non-Invasive Therapies for Gastrointestinal Cancers: What a Long, Strange Trip
It's Been!" OH 4/2015
- Ohio State Cancer Center Medical Cancer Grand Rounds, Columbus, OH 4/17/2015

MEDICAL & SERVICE INFORMATION

A. Patient Care Responsibilities

1. Hepatobiliary and gastrointestinal cancer surgical care at BSLMC, assist junior surgical oncology faculty at BTGH once or twice monthly on hepatobiliary cases.
2. Section or Specialty
 - Provide assessment, outpatient, inpatient, and surgical care for patients with hepatobiliary, pancreatic, neuroendocrine, or other gastrointestinal malignancies.

B. Clinical Research Responsibilities

Protocols – Funded:

- Collaborator, Master protocol for comparative radiolocalization of monoclonal antibodies directed to the TAG-72 antigen following intravenous administration to patients with colorectal carcinoma, ID91-016, PI - James L. Murray, 1991-1992, NCI
- Collaborator, Anemia in patients with gastric and colorectal malignancies: A pilot study to characterize the anemia and monitor the erythropoietic response to iron therapy, ID91003, PI - Merrick I. Ross, 1991-2000, Ortho
- Principal Investigator, Phase I trial of intralesional CDDP-E therapeutic implant (MP 5020) in patients with primary or metastatic cancer of the liver, ID92-017, 1992-1998, Matrix
- Collaborator, A phase II study of paclitaxel (NSC 125343) in patients with measurable biliary tract cancer, ID94-024, 1994-1997, Bristol-Myers Squibb
- Collaborator, Radioimmunosciintigraphy of occult colorectal cancer with OncoSpect (99MTC-88BV59H21-2V67-66), a totally human monoclonal antibody multicenter study, ID99-004, PI - James L. Murray, 1994-1998, Organon Teknika
- Collaborator, Postoperative radiotherapy plus chemotherapy for adjuvant treatment of operable rectal cancer, RTOG94-03, PI - John Skibber, 1994-2010, RTOG
- Collaborator, A phase II trial of systemic Platinol, recombinant human interferon alpha (RINFA 2B), Adriamycin, and 5-fluorouracil (5FU) PIAF for the treatment of biliary tract carcinoma, ID95-132, 1995-1999, Schering Plough
- Collaborator, A phase II trial of systemic Platinol, recombinant human interferon alpha (RINFA 2B), Adriamycin, and 5-fluorouracil (5FU) (PIAF) for the treatment of hepatocellular carcinoma (HCC), ID95-126, PI - Yehuda Z. Patt, 1995-2000, Schering Plough
- Principal Investigator, a two-stage phase II safety and efficacy study of intradose (cisplatin/epinephrine) injectable gel (MPI 5010) administered to patients with unresectable primary hepatocellular carcinoma, ID96-191, 1996-2000, Matrix Pharmaceuticals.
- Collaborator, Phase I trial of preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer, ID96-073, PI - Paulo Hoff, 1996-2001, Bristol-Myers Squibb
- Principal Investigator, a pilot study of radiofrequency ablation of resectable liver tumors, IDP97-221, 1997-1999, Radiotherapeutics
- Collaborator, A phase II trial of subcutaneous (SC) recombinant human interferon alpha (rINFa2b) and continuous intravenous (IV) 5-fluorouracil (5-Fu) for the treatment of hepatocellular carcinoma (HCC), DM97-040, PI - Yehuda Z. Patt, 1997-2002, Schering Plough

- Principal Investigator, A pilot study of radiofrequency ablation of unresectable liver tumors, GSP97-013, 1997-2004, Radiotherapeutics
- Collaborator, A phase I dose-escalation trial of hepatic artery infusion with an EF1Battenuated adenovirus, ONYX-015, alone and in combination with intravenous 5fluorouracil/leucovorin into patients with extra intrahepatic metastases from gastrointestinal carcinoma, ID98-184, PI - James L. Abbruzzese, 1998-2001, Onyx Pharmaceuticals

Collaborator, Phase II trial of hepatic arterial infusion of 5-fluorouracil (5-Fu) and rIFNa2b alternating with systemic infusion CPT-11 for colorectal cancer confined to the liver and refractory to systemic 5-Fu and leucovorin, DM97-272, PI - Yehuda Z. Patt, 1998-2002, Arrow, Pharmacia, Schering Plough
- Collaborator, Phase II study of radiofrequency ablation of colorectal cancer liver metastases combined with post-ablation hepatic arterial infusion of floxuridine alternating with 5-fluorouracil, ID98-035, PI - Lee Ellis, 1998-2003, Radiotherapeutics
- Principal Investigator, A phase II study of radiofrequency ablation of unresectable liver tumors, ID97-328, 1998-2006, Radiotherapeutics
- Collaborator, a phase II trial of dolastatin-10 (NSC 376128) administered as IV bolus every 3 weeks in patients with hepatobiliary cancer, ID98-169, PI - James L. Abbruzzese, 1999-2001, University of Chicago
- Collaborator, a study of the Isomed pump model 8472 for the hepatic arterial infusion of chemotherapy, ID98-300, PI - Yehuda Z. Patt, 1999-2001, Medtronic
- Collaborator, a phase II study of intravenous DX-8951F administered daily for five days every three weeks to patients with hepatocellular carcinoma, ID99-145, PI - Yehuda Z. Patt, 1999-2002, Daiichi
- Collaborator, A phase II study of the efficacy and tolerability of L-778123 in patients with metastatic colorectal or pancreatic cancer, ID99-168, PI - Linus Ho, 1999-2002, Merck, Sharp and Dohme
- Collaborator, Phase II trial of (thalidomide) as an anti-neoantigenic agent in hepatocellular carcinoma, DM98-337, PI - Yehuda Z. Patt, 1999-2002, Celgene
- Collaborator, Phase II trial of gemcitabine in the treatment of metastatic or recurrent cholangiocarcinoma/gallbladder cancer, ID98-360, PI - Yehuda Z. Patt, 1999-2002, Washington University
- Collaborator, Phase II trial of thalidomide as an anti-neoantigenic agent in biliary tract cancer (BTC), ID99-136, PI - Yehuda Z. Patt, 1999-2003, Celgene
- Collaborator, Phase II study of the efficacy of Neumega (oprelvekin) in thrombocytopenic patients with liver cirrhosis, DM99-270, PI - Yehuda Z. Patt, 2000-2002, Wyeth

- Collaborator, a phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with biliary tree cancer (cholangiocarcinoma and gallbladder cancer), ID99-379, PI - Yehuda Z. Patt, 2000-2003, Daiichi
 - Collaborator, Phase I/II single-center, dose-escalation, pharmacokinetic, safety, and efficacy study of oral TAC-101 in patients with advanced hepatocellular carcinoma, ID01007, PI - Melanie Thomas, 2001-2005, Taiho
 - Collaborator, Randomized phase II trial of preoperative combined modality chemoradiation for distal rectal cancer, RTOG R0012, PI - Christopher Crane, 2001-2010, RTOG
 - Collaborator, A pilot study for the Texas genetic TexGen consortium, LAB01-526, PI - Xifeng Wu, 2001-present, Texas Genetic Consortium
 - Collaborator, Phase I trial of concurrent weekly CPT-11, radiotherapy and Celebrex for patients presenting with metastatic colorectal cancer, ID01-359, PI - Christopher Crane, 2002-2004, Pharmacia
 - Collaborator, Phase II study of Gleevac (imatinib mesylate) in patients with metastatic or unresectable carcinoid tumors, ID01-560, PI - James Yao, 2002-2006, Ciba Geigy
 - Collaborator, Phase II study of bevacizumab and PEG interferon alpha-2B (PEG Intron) in patients with metastatic or unresectable carcinoid tumors, ID02-063, PI - James Yao, 2003-2007, NCI
 - Collaborator, Single-institution phase II trial of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) for initially unresectable colorectal liver metastases: Downstaging followed by hepatic resection, 2004-0816, PI - Eddie Abdalla, 2005-2009, Sanofi-Aventis
- Collaborator, A phase 2 study of SU011248 in Von Hippel-Lindau syndrome, 2005-0463, PI - Eric Jonasch, 2005-present, MDACC/Pfizer
- Collaborator, A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic or pulmonary metastases of colorectal carcinoma, 2006-0287, 2006-2007, Duke.
 - Collaborator, Phase I study of proton radiotherapy and bevacizumab for primary liver tumors, 2005-0881, PI - Sunil Krishnan, 2007-2009, Genentech
 - Collaborator, Blood and tumor sample collection from patients with uveal melanoma, LAB07-0262, PI - Esmaeli, Rita, 2007-present
 - Collaborator, Effects of RNA integrity and source on breast cancer genomic signatures, LAB08-0824, PI - Fraser W. Symmans, 2008-present, Breast Cancer Research Foundation

- Collaborator, A phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation, 2008-0396, PI - Jean N. Vauthey, 2010-present, Bayer

Unfunded:

- Collaborator, Human Kupffer cell cytotoxicity against human colorectal adenocarcinoma, GS89-003, PI - Barry Feig, 1989-1999
- Principal Investigator, Hepatic infusion of doxorubicin associated with complete hepatic venous isolation and extracorporeal chemofiltration: A phase I study in patients with hepatocellular carcinoma, ID90-026, 1991-1995
- Collaborator, Phase II study of cisplatin, 5-FU and leucovorin (PFL) in patients with miscellaneous adenocarcinoma of the GI tract (duodenum, small intestine, appendix), ID92-006, PI - Yehuda Z. Patt, 1992-1997
- Collaborator, Current practice of cryosurgery for unresectable hepatic metastases, CPPGS94-001, PI - Mark S. Roh, 1994-1997
- Principal Investigator, A pilot study of intratumoral injections of DTI-015 for unresectable hepatic tumors, GSP96-273, 1996-2000
- Collaborator, Phase II trial of pre-operative concomitant boost radiotherapy and continuous infusion chemotherapy for resectable rectal cancers, ID97-178, PI - Nora Janjan, 1997-2002
- Principal Investigator, Comparison of liver regeneration following hepatectomy in patients treated with neoadjuvant chemotherapy +/- bevacizumab, RC407-0093, 1997-2010
- Collaborator, Analysis of patients with locally recurrent rectal carcinoma: Prospective assessment of quality of life, outcome of therapy, and management of pain, ID97-106, PI - John M. Skibber, 1997-present
- Collaborator, Prospective evaluation of molecular markers in predicting response to preoperative adjuvant therapies in the treatment of rectal cancer, ID98-130, PI - John M. Skibber, 1998-2001
- Collaborator, Ovarian and gastrointestinal tumor antigen epitopes, LAB98-280, PI - Ralph Freedman, 1998-2002
- Principal Investigator, LBA AFP-L3 and libasys clinical patient sample collection, LAB00-300, 2000-2001
- Collaborator, Toxicity of the trail gene in primary human hepatocytes, LAB00-338, PI - Bingliang Fang, 2000-2004
- Co-Principal Investigator, *in vitro* evaluation of the durability of biliary stents coated/impregnated with antiseptics, LAB00-388, PI - Raad, Issam, 2000-2013.

- Principal Investigator, a phase I study of ADI-PEG 20 (arginine deiminase polyethylene glycol) in patients with unresectable hepatocellular carcinoma, ID01-124, 2001-2002, Phoenix Pharmacologics

- Principal Investigator, Chart review study to develop a database library for patients with liver cancer, RCR01-106, 2001-2004

Collaborator, Laboratory analysis of human endothelial progenitor cells, serum cytokines and tumor markers in normal volunteers, and in patients with metastatic colorectal cancer, LAB01-686, PI - Edward Lin, 2001-2006

- Collaborator, Expression profile analyses of a novel fragile site-associated gene in human malignancies, LAB01-237, PI - Macus T. Kuo, 2001-2010
- Collaborator, Oxidative stress and the interaction between viral hepatitis and alcohol consumption in hepatocarcinogenesis: Case-control study, ID00-083, PI - Manal Hassan, 2001-2013.
- Co-Principal Investigator, A phase II study of chrono-modulated preoperative infusional chemoradiation for biliary tract cancer, ID01-360, PI - Christopher Crane, 2002-2003
- Collaborator, A prospective study of the prognostic significance of microsatellite instability in patients with early age-of-onset colorectal cancer, ACOSOG Z0190, PI - Miguel Rodriguez-Bigas, 2002-2005, ACOSOG
- Principal Investigator, Treatment with ADI-PEG 20 (arginine deiminase polyethylene glycol) in humans having unresectable hepatocellular carcinoma (HCC), ID02-228, 2002-2006, Phoenix Pharmacologics.
- Collaborator, Markers of distant metastasis in breast cancer, LAB02-647, PI - Funda Meric-Bernstam, 2002-2011
- Collaborator, Collection and banking of blood and tissue samples from patients with gastrointestinal malignancies: An endoscopic and surgical banking protocol, LAB01-543, PI - Jaffer Ajani, 2002-2013.
- Collaborator, Neuroendocrine carcinoma database, RCR01-701, PI - James Yao, 2002-2013.
- Collaborator, Collection of blood samples and miscellaneous tissue samples from participants with carcinoid, pancreatic islet cell, and other neuroendocrine tumors: A laboratory protocol, LAB03-0171, PI - Linus Ho, 2003-2004
- Collaborator, Laboratory protocol for collection of residual tissue and sample analyses from patients with cholangiocarcinoma (gallbladder and biliary cancer tract), LAB030412, PI - Ahmed Kaseb, 2003-2011
- Principal Investigator, Resectional and ablative therapy for non-colorectal metastatic liver tumors: An analysis of factors predicting success and durability, RCR03-0654, 2003p-2010.

- Co-Principal Investigator, Collection of blood, other body fluids, residual tissue, and/or data for patients with known or suspected gastrointestinal malignancies, LAB03-0913, PI - James Yao, 2004-2013.
- Collaborator, Diabetes as a predictor of length of hospital stay in cancer surgery patients, RCR04-0934, PI - Jane Geraci, 2005-2006
- Co-Principal Investigator, Pilot study of image-guided radiation therapy using implanted fiducial markers in hepatobiliary tumors, 2005-0024, PI - Sunil Krishnan, 2005-2008
- Collaborator, Phase I study of paclitaxel administered by hepatic artery infusion to patients with advanced cancer and concomitant liver involvement, 2005-0092, PI - Apostolia Tsimberidou, 2005-2010
- Collaborator, a phase I study of hepatic arterial infusion of oxaliplatin in combination with systemic fluorouracil, leucovorin and Avastin for patients with advanced tumors metastatic to the liver, 2006-0106, PI - Apostolia Tsimberidou, 2006-2010
- Collaborator, Surgical complications in patients receiving bevacizumab for metastatic colorectal cancer, RCR06-0650, PI - Barry Feig, 2006-2011
- Co-Principal Investigator, Multicenter feasibility study of percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients, ACRIN06-6673, PI - Kamran Ahrar, 2006-present, ACRIN/NCI
- Principal Investigator, Comparison of liver regeneration following hepatectomy in patients treated with neoadjuvant chemotherapy +/- bevacizumab, RCR07-0093, 2007-2010 Co-Principal Investigator, does liver hanging maneuver improve the outcome of complex hepatic resections: A matched-case control study, DR07-0531, 2007-2013.
- Principal Investigator, Determination of circulating microRNAs as unique cancer biomarkers, LAB08-0768, 2008-2010
- Principal Investigator, Outcomes in surgical oncology care: What's really important, DR09-0590, 2009-2010
- Principal Investigator, Evaluation of stapler use in HCC, gall bladder cancer, and cholangiocarcinoma, DR09-0767, 2009-2018.
- Principal Investigator, Evaluation of hepatic resection of neuroendocrine metastases, DR09-0766, 2010-2011
- Co-Principal Investigator, A phase I clinical trial of hepatic arterial infusion of oxaliplatin, oral capecitabine, with or without systemic bevacizumab for patients with advanced cancer metastatic to the liver, 2010-0413, PI - Issam Raad, 2010-2013.

- Principal Investigator, Assessment of patient attitudes towards cost of cancer care, PA110960, 2011-present
- Collaborator, Noninvasive assessment of tumor mutation status in circulating free DNA in metastatic colorectal cancer, LAB10-0340, PI - Meric, Funda, 2011-2013.
- Collaborator, Postoperative pain management after hepatic resection: A retrospective comparison of epidural analgesia of IV PCA with OnQ infiltrating catheter, DR10-0973, PI - Soliz, Jose, 2011
- Principal Investigator, Surgical management of non-colorectal metastatic disease to the liver: A single center experience, PA11-1076, 2012-2018.

C. National Education or Voluntary Health Organization Participation

- Member, Treatment and Guidelines Group, Hepatobiliary Cancer, National Comprehensive Cancer Network, Houston, 1/1999-2017
- Member, Commission on Cancer Liver Disease Site Team, American College of Surgeons, Houston, 1/2002-present
- External Reviewer, The Cancer Therapy Evaluation Program, Department of Health and Human Services, Houston, 1/2005-2015
- Member, Organizing Committee, 5th International Hepatocellular Carcinoma: Eastern and Western Experiences Conference, Houston, 1/2006-1/2007
- Member, Lifeboat Foundation, Scientific Advisory Board, Houston, TX, 11/2007-present
- Member, GE Healthcare GI Cancers, Advisory Board, Houston, TX, 11/2007-2018
- Director, Department of Surgical Oncology IT Services, Houston, TX, 2008-2011
- Member, NCI Special Emphasis Panel for Cancer Nanotechnology Platform Partnerships (UO1), Washington, DC, 2009-2015
- Member, Executive Committee, Society of Surgical Oncology, Arlington Heights, IL, 2010-2016

D. Administrative Assignments

1. Department Administration, Committees, etc.

- Medical Director, Gastrointestinal Cancer Multidisciplinary Care Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1995-2013
- Chief, Gastrointestinal Tumor Surgery, Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1993-2013 •
- Medical Director, General Surgery Physicians' Assistants, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1991-1/1997

- Director, Surgical Oncology Fellowship Program, Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1990-9/2009
- Medical Director, Station 80, General Surgery Clinic, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1991-1/1996
- Advisor, TMC Innovation Institute, Houston, TX, 8/2017 - present

2. College, School or University Administration, Committees, etc.

- Intensive Care Planning Committee, Member, 1/1990-1/1992
- Graduate Medical Education Committee, Member, 1/1991-2014
- Executive Committee, Department of General Surgery, Member, 1/1992-1/1993
- Surveillance Committee, Member, 1/1992-1/1994
- Clinic Planning Steering Committee, Member, 1/1993-2014
- Faculty Senate Ethics Committee, Member, 1/1994-1/1996
- Graduate Medical Education Committee, Chairman, 1/1994-1/1996
- Clinical Council Subcommittee on Clinical Research Funding, Member, 1/2001-2014
- Training Committee, Division of Surgery Annual Retreat, Chairman, 1/2003-2004
- GI Center Specialties Project Committee, Member, 2008-2014
- Enterprise Internet Strategy Physician and Scientist Access Workgroup, Member, 5/2008-2014
- Volume Outcome Relationship in Cancer Surgery Committee, Member, 2009-2016
- PhD Program in Clinical Science Executive Committee, Member, 7/2009-2018
- Executive Committee, Division of Surgery, Member, 2010-2012
- Clinical Revenue Cycle Committee, Member, 2010-2014
- Global Academic Programs Advisory Committee, Member, 2010-2018
- PRS Faculty Compensation and Benefit Advisory Committee, Member, 2011-2014
- Department of Surgery Council on Clinical Research, Member, 2012-2014
- Executive Committee, Member, 2014- 2018
- Medical Director Committee, Member, 2014- 2018
- Department of Surgery Research Committee, Member, 2014- 2018
- BSLMC Cancer Committee, Member, 2014- 2018

- BCM Medical Directors Committee, Member, 2014- 2018
- Christus Trinity Mother Frances Institute Directors, 2018- present
- Christus Trinity Mother Frances Service Chiefs, 2018- present

E. Other Pertinent Information (not given above)

- Surgical Mission Volunteer in Central and South America annually for 12 years
- Volunteer work with Operation Underground Railroad to assist children entrapped or enslaved in the U.S. or other countries in illegal sex trade.
- Volunteer at The Women's Home in Houston, Texas for recovering addicts.

Revised: August 1, 2024.